Methods of treating chronic lymphocytic leukemia with 2-(2,6-dioxopiperidin-3-yl)-4-((2-fluoro-4-((3-morpholinoazetidin-1-yl)methyl)benzyl)amino)isoindoline-1,3-dione
The compound 2-(2,6-dioxopiperidin-3-yl)-4-((2-fluoro-4-((3-morpholinoazetidin-1-yl)methyl)benzyl)amino)isoindoline-1,3-dione, combined with obinutuzumab, addresses drug resistance in CLL/SLL by offering a novel therapeutic strategy that enhances treatment efficacy and survival outcomes.
Patent Information
- Application Number
- JP2022523519
- Authority / Receiving Office
- JP · JP
- Patent Type
- Patents
- Current Assignee / Owner
- Priority Date
- 2020-04-16
- Filing Date
- 2020-10-20
- Publication Date
- 2024-11-12
- Estimated Expiration
- 2040-10-20
AI Technical Summary
Current treatments for chronic lymphocytic leukemia (CLL) are limited by drug resistance, severe side effects, and inadequate response rates, particularly in relapsed or refractory cases, necessitating the development of alternative therapeutic options with novel mechanisms of action.
The use of 2-(2,6-dioxopiperidin-3-yl)-4-((2-fluoro-4-((3-morpholinoazetidin-1-yl)methyl)benzyl)amino)isoindoline-1,3-dione, alone or in combination with obinutuzumab, to treat CLL/SLL, targeting distinct pathways to overcome resistance and enhance treatment efficacy.
This approach provides therapeutic benefits in CLL/SLL, including improved response rates, increased survival, and reduced disease progression, particularly in relapsed or refractory cases, by leveraging a unique mode of action.
Smart Images

Figure 0007581345000033 
Figure 0007581345000034 
Figure 0007581345000001
Abstract
Description
[Technical field]
[0001] This application claims priority to U.S. Provisional Patent Application No. 62 / 923,955, filed October 21, 2019, and U.S. Provisional Patent Application No. 63 / 011,147, filed April 16, 2020, the contents of which are incorporated herein by reference in their entireties.
[0002] Provided herein are methods of using 2-(2,6-dioxopiperidin-3-yl)-4-((2-fluoro-4-((3-morpholinoazetidin-1-yl)methyl)benzyl)amino)isoindoline-1,3-dione, or an enantiomer, mixture of enantiomers, tautomer, isotopologue, or a pharma- ceutically acceptable salt thereof, alone or in combination with obinutuzumab, to treat, prevent, or manage chronic lymphocytic leukemia / small lymphocytic lymphoma (CLL / SLL). [Background technology]
[0003] Cancer is primarily characterized by an increase in the number of abnormal cells originating from a given normal tissue, the invasion of adjacent tissues by these abnormal cells, or the spread of malignant cells via lymph or blood to regional lymph nodes, and metastasis. Clinical data and molecular biological studies indicate that cancer growth is a multistep process that begins with minor prebiotic changes that may develop into neoplasms under certain conditions. The neoplastic lesions may evolve clonally and develop increasing capacities for invasion, proliferation, metastasis, and heterogeneity, especially under conditions that allow the neoplastic cells to escape the host's immune surveillance. Current cancer therapies include surgery, chemotherapy, hormonal therapy, and / or radiation therapy to eradicate the neoplastic cells in the patient. Recent advances in cancer therapy are reviewed by Rajkumar et al. in Nature Reviews Clinical Oncology 11, 628-630 (2014).
[0004] All current cancer therapies have significant drawbacks for patients. For example, surgery may be avoided by the patient's health condition or may be unacceptable to the patient. In addition, surgery may not completely remove the neoplastic tissue. Radiotherapy is only effective if the neoplastic tissue is more sensitive to radiation than normal tissue. Radiotherapy may also cause severe side effects. Hormonal therapy is rarely applied as a single agent. Although hormone therapy can be effective, it is often used to prevent or delay the recurrence of cancer after other treatments have removed the majority of the cancer cells.
[0005] Despite the availability of a variety of chemotherapy agents, chemotherapy has many drawbacks. Almost all chemotherapy agents are toxic, and chemotherapy causes significant and sometimes dangerous side effects, including severe nausea, bone marrow suppression, and immunosuppression. In addition, many tumor cells are resistant or evolve resistance to chemotherapy agents, even when administered in combination. In fact, those cells that are resistant to a particular chemotherapy agent used in a treatment protocol often also resist other drugs, even if those agents function by a different mechanism of action than the drug used in the particular treatment. This phenomenon is called multidrug resistance or multiple drug resistance. Because of this drug resistance, many cancers are or become refractory to standard chemotherapy treatment protocols.
[0006] Chronic lymphocytic leukemia (CLL) is a lymphoproliferative malignancy characterized by the progressive accumulation of morphologically mature but functionally insufficient B lymphocytes with distinct clusters of differentiation (CDs) CD19+, CD5+, and CD23+ phenotypes in blood, bone marrow, and lymphoid tissues. It is the most common leukemia in North America and Europe with an incidence rate of 4.0 per 100,000 per year, affecting mostly older patients with a median age at onset of 72 years. The clinical course of CLL ranges from an indolent disease with prolonged survival of more than 12 years to an aggressive disease with a median survival of 2 years, influenced by the stage at presentation and certain disease-specific features such as cytogenetic abnormalities. The current clinical course and prognosis reflect the evolution of the therapeutic landscape, including the emergence of new agents available for the treatment of CLL. Despite the recent introduction of several highly effective agents, CLL remains an incurable disease for patients who do not undergo allogeneic stem cell transplantation, therefore necessitating the development of alternative and additional treatment options.
[0007] The molecular pathogenesis of CLL / SLL represents a complex and multifaceted process characterized by specific genetic abnormalities, alterations in cell signaling pathways, including B cell receptors and apoptotic pathways, and the convergence of the tumor-immune microenvironment. The term CLL is used when the disease is primarily manifested in the blood, whereas the term small lymphocytic lymphoma (SLL) is used when the disease is primarily metastatic to lymph nodes. Specifically, SLL, as defined by the International Workshop on Chronic Lymphocytic Leukemia (iwCLL) criteria, is a disease in patients who are otherwise diagnosed with CLL, but who have relatively normal peripheral lymphocyte counts and require the presence of lymphadenopathy and / or splenomegaly. In contrast to CLL, which is more prevalent in blood and bone marrow, as well as other disease sites such as lymph nodes, spleen, and extranodal sites, patients with SLL have less prominent signs in the peripheral blood.
[0008] The CLL treatment landscape is evolving, as evidenced by the recent approval of several novel targeted agents, such as ibrutinib and venetoclax. However, despite the availability of these new agents, patients continue to relapse or are refractory to treatment. Moreover, patients with low-risk cytogenetic features continue to show worse outcomes compared to patients without these features. Improved and novel combination therapies for CLL will continue to be a significant medical need. In addition, the increased use of targeted therapeutics has led to the emergence of new mutations that confer resistance to treatment. For example, resistance to the BTK inhibitor ibrutinib is associated with either mutations at the BTK binding site or mutations that result in autonomous B-cell receptor activity. Therefore, exploring agents with novel mechanisms is important to provide treatment options with unique mechanisms of action (MOA) for patients who develop resistance to the emergence of targeted agents.
[0009] Citation or identification of any reference in this section of this application shall not be construed as an admission that such reference is prior art to the present application. Summary of the Invention
[0010] Provided herein are methods of using 2-(2,6-dioxopiperidin-3-yl)-4-((2-fluoro-4-((3-morpholinoazetidin-1-yl)methyl)benzyl)amino)isoindoline-1,3-dione, or an enantiomer, mixture of enantiomers, tautomer, isotopologue, or a pharma- ceutically acceptable salt thereof, alone or in combination with obinutuzumab, to treat, prevent, or manage CLL / SLL.
[0011] In certain embodiments, provided herein is a method of treating CLL / SLL, comprising administering to a subject in need of such treatment a therapeutically effective amount of a compound of the formula: [ka] The method includes administering compound 1, which is represented by the formula:
[0012] In certain embodiments, provided herein is a method of treating CLL / SLL, comprising administering to a subject in need of such treatment a therapeutically effective amount of a compound of the formula: [ka] The method includes administering compound 2, which is represented by the formula:
[0013] In certain embodiments, provided herein is a method of treating CLL / SLL, comprising administering to a subject in need of such treatment a therapeutically effective amount of a compound of the formula: [ka] or an enantiomer, mixture of enantiomers, tautomer, isotopologue, or a pharma- ceutically acceptable salt thereof.
[0014] In certain embodiments, provided herein is a compound for use in a method for treating chronic lymphocytic leukemia / small lymphocytic lymphoma (CLL / SLL), the compound having the formula: [ka] or an enantiomer, mixture of enantiomers, tautomer, isotopologue, or pharma- ceutically acceptable salt thereof, wherein the method comprises administering to a subject in need thereof a therapeutically effective amount of the compound.
[0015] In certain embodiments, provided herein is a compound for use in a method for treating chronic lymphocytic leukemia / small lymphocytic lymphoma (CLL / SLL), the compound having the formula: [ka] or a tautomer, isotopologue, or pharma- ceutically acceptable salt thereof, wherein the method comprises administering to a subject in need thereof a therapeutically effective amount of the compound.
[0016] In certain embodiments, provided herein is a compound for use in a method for treating chronic lymphocytic leukemia / small lymphocytic lymphoma (CLL / SLL), the compound having the formula: [ka] or a tautomer, isotopologue, or pharma- ceutically acceptable salt thereof, wherein the method comprises administering to a subject in need thereof a therapeutically effective amount of the compound.
[0017] In certain embodiments, the CLL / SLL is relapsed or refractory CLL / SLL.
[0018] In certain embodiments, methods provided herein further comprise administering to the subject a therapeutically effective amount of obinutuzumab.
[0019] The present embodiments may be more fully understood by reference to the detailed description and examples given by way of example and not of limitation. [Brief description of the drawings]
[0020] [Figure 1]1 shows a heat map of normalized percentage of tumor cells following treatment with Compound 1 in combination with obinutuzumab. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0021] definition Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by those skilled in the art. All patents, applications, publications and other publications are incorporated herein in their entirety by reference. In the event that there are multiple definitions for a term herein, the definition in this section shall prevail unless otherwise stated.
[0022] As used herein and in the specification and the appended claims, the indefinite articles "a" and "an" and the definite article "the" include plural as well as singular referents unless the context clearly dictates otherwise.
[0023] As used herein, the words "comprise" and "comprise" may be used interchangeably. The words "comprise" and "comprise" may be interpreted as specifying the presence of the features or components described as referred to, but do not exclude the presence or addition of one or more features or components or groups thereof. In addition, the words "comprise" and "comprise" are intended to include examples encompassed by the word "comprise". As a result, the word "comprise" may be used in place of the words "comprise" and "comprise" to provide more specific embodiments of the present invention.
[0024] The term "consisting of" means that the subject matter has at least 90%, 95%, 97%, 98% or 99% of the recited features or components that make it up. In another embodiment, the term "consisting of" excludes from the scope of any succeeding recitation any other features or components, except those that are not essential to the technical effect to be achieved.
[0025] As used herein, the word "or" should be interpreted as an inclusive "or", meaning any one or any combination. Thus, "A, B or C" means any of the following: "A; B; C; A and B; A and C; B and C; A, B and C." Exceptions to this definition will occur only if combinations of elements, features, steps or acts are, in some sense, inherently mutually exclusive.
[0026] As used herein, the term "pharmaceutical acceptable salts" refers to salts prepared from pharmaceutical non-toxic acids or bases, including inorganic acids and bases, and organic acids and bases. Suitable pharmaceutical acceptable base addition salts of the compounds provided herein include, but are not limited to, metallic salts prepared from aluminum, calcium, lithium, magnesium, potassium, sodium, and zinc, or organic salts prepared from lysine, N,N'-dibenzylethylenediamine, chloroprocaine, choline, diethanolamine, ethylenediamine, meglumine (N-methyl-glucamine), and procaine. Suitable non-toxic acids include, but are not limited to, inorganic and organic acids such as acetic acid, alginic acid, anthranilic acid, benzenesulfonic acid, benzoic acid, camphorsulfonic acid, citric acid, ethenesulfonic acid, formic acid, fumaric acid, furoic acid, galacturonic acid, gluconic acid, glucuronic acid, glutamic acid, glycolic acid, hydrobromic acid, hydrochloric acid, isethionic acid, lactic acid, maleic acid, malic acid, mandelic acid, methanesulfonic acid, mucic acid, nitric acid, pamoic acid, pantothenic acid, phenylacetic acid, phosphoric acid, propionic acid, salicylic acid, stearic acid, succinic acid, sulfanilic acid, sulfuric acid, tartaric acid, and p-toluenesulfonic acid. Others are well known in the art and are described, for example, in Remington's Pharmaceutical Sciences, 18 theds., Mack Publishing, Easton PA (1990) or Remington: The Science and Practice of Pharmacy, 19th eds., Mack Publishing, Easton PA (1995).
[0027] As used herein and unless otherwise specified, the term "stereoisomer" or "stereoisomerically pure" refers to one stereoisomer of a compound that is substantially free of other stereoisomers of that compound. For example, a stereoisomerically pure compound having one chiral center will be substantially free of the opposite enantiomer of the compound. A stereoisomerically pure compound having two chiral centers will be substantially free of other diastereomers of the compound. A typical stereoisomerically pure compound comprises about 80% or more by weight of one stereoisomer of the compound and less than about 20% by weight of other stereoisomers of the compound, about 90% or more by weight of one stereoisomer of the compound and less than about 10% by weight of other stereoisomers of the compound, about 95% or more by weight of one stereoisomer of the compound and less than about 5% by weight of other stereoisomers of the compound, or about 97% or more by weight of one stereoisomer of the compound and less than about 3% by weight of other stereoisomers of the compound. The compounds may contain chiral centers and may exist as racemates, individual enantiomers or diastereomers, and mixtures thereof. All such isomeric forms, including mixtures thereof, are included within the embodiments provided herein.
[0028] The use of stereomerically pure forms of such compounds, as well as the use of mixtures of those forms, are encompassed by the embodiments provided herein. For example, mixtures containing equal or unequal amounts of enantiomers of a particular compound may be used in the methods and compositions provided herein. These isomers may be asymmetrically synthesized or resolved using standard techniques, such as chiral columns or chiral resolving agents. For example, Jacques, J. et al., Enantiomers, Racemates and Resolutions (Wiley-Interscience, New York, 1981); Wilen, SH et al., Tetrahedron 33:2725 (1977); Eliel, EL, Stereochemistry of Carbon Compounds (McGraw-Hill, NY, 1962); Wilen, SH, Tables of Resolving Agents and Optical Resolutions p. 268(EL Eliel, Ed., Univ. of Notre Dame Press, Notre Dame, IN, 1972);Todd, M., Separation Of Enantiomers: Synthetic Methods(Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim, Germany, 2014);Toda, F., Enantiomer Separation: Fundamentals and Practical Methods(Springer Science & Business Media, 2007);Subramanian, See G., Chiral Separation Techniques: A Practical Approach (John Wiley & Sons, 2008); Ahuja, S., Chiral Separation Methods for Pharmaceutical and Biotechnological Products (John Wiley & Sons, 2011).
[0029] It should be understood that the compounds provided herein may contain chiral centers. Such chiral centers may be in either the (R) or (S) configuration, or may be a mixture thereof. It should be recognized that the chiral centers of the compounds provided herein may undergo epimerization in vivo. Thus, one skilled in the art will recognize that administration of a compound in its (R) form is equivalent to administration of the compound in its (S) form for compounds that undergo epimerization in vivo.
[0030] Optically active (+) and (-), (R)- and (S)-, or (D)- and (L)-isomers may be prepared using chiral syntheses or chiral reagents, or resolved using conventional techniques, such as chromatography on chiral stationary phases.
[0031] "Tautomers" refer to isomeric forms of a compound that are in equilibrium with one another. The concentration of isomeric forms will depend on and may vary depending on the environment in which the compound is found, for example, whether the compound is a solid or in an organic or aqueous solution. For example, in aqueous solution, pyrazole may exhibit the following isomeric forms, which are referred to as tautomers of each other: [ka]
[0032] As will be readily understood by one of ordinary skill in the art, a wide variety of functional groups and other structures may exhibit tautomerism, and all tautomers of the compounds are within the scope of the compounds provided herein.
[0033] It should also be noted that the compounds provided herein may contain unnatural proportions of atomic isotopes at one or more atoms. For example, the compounds may contain, for example, tritium ( 3 H), iodine-125( 125 I), Sulfur-35( 35 S) or carbon-14 ( 14It may be radiolabeled with a radioisotope such as C, or it may be radiolabeled with deuterium ( 2 H), Carbon-13( 13 C) or nitrogen-15( 15 As used herein, an "isotopologue" is an isotope-enriched compound. The term "isotopically enriched" refers to an atom having an isotopic composition different from the natural isotopic composition of that atom. "Isotopically enriched" also refers to a compound containing at least one atom having an isotopic composition different from the natural isotopic composition of that atom. The term "isotopic composition" refers to the amount of each isotope present for a given atom. Radiolabeled, isotopically enriched compounds are useful as therapeutic agents, e.g., cancer therapeutic agents, research agents, e.g., binding assay agents, and diagnostic agents, e.g., in vivo imaging diagnostic agents. Any and all isotopic variations of compounds, either radioactive or not, are also intended to be included within the scope of the compounds provided herein. In some embodiments, provided herein are isotopologues of compounds, e.g., isotopologues are deuterium, carbon-13 ( 13 C) and / or nitrogen-15( 15 As used herein, "deuterated" refers to a compound in which at least one hydrogen (H) is replaced with a deuterium (D or 2 H), meaning that the compound is enriched in deuterium at at least one position.
[0034] It is understood that each of the compounds provided herein can be provided in the form of any of the pharmaceutically acceptable salts provided herein, independent of stereoisomeric or isotopic composition.Similarly, it is understood that the isotopic composition can vary independently of the stereoisomeric composition of each compound provided herein.Furthermore, while the isotopic composition is limited to those elements present in each compound or its salt, its composition can vary independently of the choice of the pharmaceutically acceptable salt of that each compound.
[0035] It should be noted that in the event of a discrepancy between a depicted structure and a name given to that structure, the depicted structure carries more weight.
[0036] As used herein and unless otherwise indicated, the term "treat" means to alleviate, in whole or in part, a disorder, disease or condition, or one or more symptoms associated with a disorder, disease or condition, or to slow or halt the further progression or worsening of such symptoms, or to reduce or eradicate the etiology of the disorder, disease or condition itself.
[0037] As used herein and unless otherwise specified, the term "prevent" refers to a method of delaying and / or preventing the onset, recurrence or spread of a disorder, disease or condition, in whole or in part; barring a subject from acquiring a disorder, disease or condition; or reducing the risk that a subject will acquire a disorder, disease or condition.
[0038] As used herein and unless otherwise indicated, the term "manage" includes preventing the recurrence of a particular disease or disorder in a patient who has had the disease or disorder, prolonging the time in remission in a patient who has had the disease or disorder, reducing the mortality rate of the patient, and / or maintaining a reduction in the severity or avoidance of symptoms associated with the disease or condition being managed.
[0039] As used herein and unless otherwise specified, the term "effective amount" in reference to a compound means an amount capable of treating, preventing or managing a disorder, disease or condition, or a symptom thereof.
[0040] As used herein and unless otherwise specified, the term "subject" or "patient" includes, but is not limited to, animals, such as cows, monkeys, horses, sheep, pigs, chickens, turkeys, quail, cats, dogs, mice, rats, rabbits, or guinea pigs, mammals in one embodiment, and humans in another embodiment.
[0041] As used herein, unless otherwise specified, the term "relapse" refers to a disorder, disease, or condition that has responded to treatment (e.g., achieved a complete response) and then progressed. Treatment can include one or more lines of therapy. In one embodiment, the disorder, disease, or condition has previously been treated with one or more lines of therapy. In another embodiment, the disorder, disease, or condition has previously been treated with one, two, three, or four lines of therapy.
[0042] As used herein and unless otherwise specified, the term "refractory" refers to a disorder, disease, or condition that is unresponsive to prior treatment, which may include one or more lines of therapy. In one embodiment, the disorder, disease, or condition has been previously treated with two or more lines of therapy and has not achieved a complete response (CR) to a regimen including the most recent systemic therapy.
[0043] In one embodiment, "relapsed or refractory" CLL / SLL can refer to CLL / SLL that has been previously treated with one or more lines of therapy. In one embodiment, relapsed or refractory CLL / SLL is CLL / SLL that has been previously treated with one, two, three or four lines of therapy. In one embodiment, relapsed or refractory CLL / SLL is CLL / SLL that has been previously treated with two or more lines of therapy. In one embodiment, relapsed or refractory CLL / SLL is CLL / SLL that has been previously treated with an inhibitor of B-cell receptor signaling. In one embodiment, relapsed or refractory CLL / SLL is relapsed or refractory to an inhibitor of B-cell receptor signaling. In one embodiment, relapsed or refractory CLL / SLL is CLL / SLL that has been previously treated with a Bruton's tyrosine kinase (BTK) inhibitor. In one embodiment, the relapsed or refractory CLL / SLL is relapsed or refractory to a BTK inhibitor. In one embodiment, the BTK inhibitor is ibrutinib. In one embodiment, the BTK inhibitor is acalabrutinib. In one embodiment, the BTK inhibitor is zanubrutinib. In one embodiment, the BTK inhibitor is tirabrutinib. In one embodiment, the relapsed or refractory CLL / SLL is CLL / SLL that has been previously treated with a phosphoinositide 3-kinase (PI3K) inhibitor. In one embodiment, the relapsed or refractory CLL / SLL is relapsed or refractory to a PI3K inhibitor. In one embodiment, the PI3K inhibitor is duvelisib. In one embodiment, the PI3K inhibitor is idelalisib. In one embodiment, the relapsed or refractory CLL / SLL is CLL / SLL that has been previously treated with venetoclax. In one embodiment, the relapsed or refractory CLL / SLL is relapsed or refractory to venetoclax. In one embodiment, the relapsed or refractory CLL / SLL is CLL / SLL that has been previously treated with obinutuzumab.In one embodiment, the relapsed or refractory CLL / SLL is relapsed or refractory to obinutuzumab.
[0044] In the context of cancer, inhibition can be evaluated by, among others, inhibition of disease progression, inhibition of tumor growth, reduction of primary tumors, alleviation of tumor-related symptoms, inhibition of tumor secreted factors, delay of appearance of primary or secondary tumors, delay of progression of primary or secondary tumors, reduction of occurrence of primary or secondary tumors, delay of secondary effects of disease or reduction of their severity, arrest of tumor growth and tumor regression, increase in time to progression (TTP), increase in progression-free survival (PFS), increase in overall survival (OS). OS as used herein means the time from the start of treatment to death from any cause. TTP as used herein means the time from the start of treatment to tumor progression; TTP does not include death. In one embodiment, PFS means the time from the start of treatment to tumor progression or death. In one embodiment, PFS means the time from the first administration of the compound to the first occurrence of disease progression or death from any cause. In one embodiment, the rate of PFS is calculated using Kaplan-Meier estimation method. Event-free survival (EFS) refers to the time from the start of treatment to any treatment failure, including tumor progression, discontinuation of treatment for any reason, or death. In one embodiment, overall response rate (ORR) refers to the proportion of patients who achieve a response. In one embodiment, ORR refers to the combined proportion of patients who achieve a complete and partial response. In one embodiment, ORR refers to the best response. > It means the proportion of patients with a partial response (PR). In one embodiment, duration of response (DoR) is the time from achieving a response to relapse or disease progression. In one embodiment, DoR is the time from achieving a response to relapse or disease progression. > It is the time from achieving a partial response (PR) to relapse or disease progression. In one embodiment, DoR is the time from the first documentation of a response to the first documentation of progressive disease or death. In one embodiment, DoR is the time from the first documentation of a response to the first documentation of progressive disease or death. >It is the time from the first documentation of a partial response (PR) to the first documentation of progressive disease or death. In one embodiment, time to response (TTR) means the time from the first administration of a compound to the first documentation of a response. In one embodiment, TTR means the time from the first administration of a compound to the first documentation of a response. > It means the time to the first documentation of a partial response (PR). At the extreme, complete inhibition is referred to herein as prevention or chemoprevention. In this context, the term "prevention" includes either preventing the onset of clinically evident cancer or preventing the onset of cancer at a preclinically evident stage. This definition is also intended to include preventing transformation into malignant cells or arresting or reversing the progression of premalignant cells to malignant cells. This includes prophylactic treatment for people at risk of developing cancer.
[0045] In one embodiment, the therapeutic response of CLL / SLL can be evaluated by the International Workshop on Chronic Lymphocytic Leukemia criteria (see Hallek, M et al., iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL. Blood, 131(25), 2745-2760(2018)) (Table 1). In one embodiment, the therapeutic response of CLL / SLL may be assessed by the International Workshop Lyphoma Response Criteria (see Cheson BD, Fisher RI, Barrington SF, Cavalli F, Schwartz LH, Zucca E, et al. Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J Clin Oncol. 2014; 32(27):3059-3068) (Table 1a).
[0046] Table 1: Definitions of response after treating patients with chronic lymphocytic leukemia [Table 1] CR = complete remission (all criteria must be met); PD = progressive disease (at least one criterion in group A or B must be met); PR = partial remission (for PR, at least two parameters in group A and one parameter in group B must improve if they were previously abnormal; if only one parameter in both groups A and B was abnormal before treatment, only one must improve); SD = stable disease (all criteria must be met; PD should not be determined solely by congenital symptoms). a Total lymph node products of 6 or less (assessed by CT scan and physical exam in clinical trials or by physical exam in general practice) b Spleen size is considered normal if it is less than 13 cm. No clear international consensus has been established regarding normal liver size; therefore, in clinical trials liver size should be assessed by imaging and palpation and documented according to the definition used in the study protocol.
[0047] Table 1a: Summary of revised criteria for assessing response [Table 2] [Table 3] Abbreviations: 5PS: 5-point scale; CR = complete response; CT = computed tomography; FDG = fluorodeoxyglucose; PET = positron emission tomography; PR = partial response; PD = progressive disease; SD = stable disease; SPD = sum of perpendicular diameter products for multiple lesions.
[0048] In one embodiment, the therapeutic response of CLL / SLL can be assessed by performance status according to the Eastern Cooperative Oncology Group (ECOG) (Table 2).
[0049] Table 2: ECOG general status [Table 4] ECOG=Eastern Cooperative Oncology Group, Robert Comis, MD, Group Chair. Source: Oken M et al., Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol, 5(6):649-655(1982)
[0050] In certain embodiments, stable disease or lack thereof may be measured by methods known in the art, such as evaluation of the patient's symptoms, physical examination, visualization of the tumor as imaged using, for example, PDG-PET (fluorodeoxyglucose-positron emission tomography), PET / CT (positron emission tomography / computed tomography) scans, MRI (magnetic resonance imaging) of the brain and spine, CSF (cerebrospinal fluid), ophthalmic examination, vitreous fluid sampling, retinal photography, bone marrow evaluation, and other commonly recognized evaluation modalities.
[0051] As used herein, and unless otherwise specified, the terms "co-administration" and "combination" include administration of one or more therapeutic agents (e.g., a compound provided herein and another anti-CLL / SLL agent or palliative treatment agent) either simultaneously, together, or sequentially, without specific time limitations. In one embodiment, the therapeutic agents are present in a cell or in a patient's body at the same time, or exert their biological or therapeutic effects at the same time. In one embodiment, the therapeutic agents are in the same composition or unit dosage form. In another embodiment, the therapeutic agents are in separate compositions or unit dosage forms.
[0052] The term "symptomatic agent" refers to any substance that treats, prevents, or manages side effects resulting from treatment with another therapeutic agent.
[0053] As used herein, unless otherwise specified, the terms "about" and "approximately", when used in relation to a dose, amount, or weight percent of a component of a composition or dosage form, refer to a dose, amount, or weight percent that is understood by those skilled in the art to provide the equivalent pharmacological effect obtained from that specific dose, amount, or weight percent.In one embodiment, the terms "about" and "approximately", when used in this context, refer to a dose, amount, or weight percent that is within 30%, within 20%, within 15%, within 10%, or within 5% of that specific dose, amount, or weight percent.
[0054] compound Provided for use in the methods provided herein is (S)-2-(2,6-dioxopiperidin-3-yl)-4-((2-fluoro-4-((3-morpholinoazetidin-1-yl)methyl)benzyl)amino)isoindoline-1,3-dione (referred to as "Compound 1"): [ka] or a tautomer, isotopologue, or a pharma- ceutically acceptable salt thereof. Provided herein is Compound 1 for use in the methods of treatment provided herein.
[0055] Also provided for use in the methods provided herein is (R)-2-(2,6-dioxopiperidin-3-yl)-4-((2-fluoro-4-((3-morpholinoazetidin-1-yl)methyl)benzyl)amino)isoindoline-1,3-dione (referred to as "Compound 2"): [ka] or a tautomer, isotopologue, or a pharma- ceutically acceptable salt thereof. Provided herein is compound 2 for use in the methods of treatment provided herein.
[0056] Provided for use in the methods provided herein is 2-(2,6-dioxopiperidin-3-yl)-4-((2-fluoro-4-((3-morpholinoazetidin-1-yl)methyl)benzyl)amino)isoindoline-1,3-dione (referred to as "Compound 3"): [ka] or an enantiomer, mixture of enantiomers, tautomer, isotopologue, or pharma- ceutically acceptable salt thereof. Provided herein is compound 3 for use in the methods of treatment provided herein.
[0057] In one embodiment, Compound 1 is used in the methods provided herein. In one embodiment, a tautomer of Compound 1 is used in the methods provided herein. In one embodiment, an isotopologue of Compound 1 is used in the methods provided herein. In one embodiment, a pharma- ceutically acceptable salt of Compound 1 is used in the methods provided herein.
[0058] In one embodiment, compound 2 is used in the methods provided herein. In one embodiment, a tautomer of compound 2 is used in the methods provided herein. In one embodiment, an isotopologue of compound 2 is used in the methods provided herein. In one embodiment, a pharma- ceutically acceptable salt of compound 2 is used in the methods provided herein.
[0059] In one embodiment, compound 3 is used in the methods provided herein. In one embodiment, an enantiomer of compound 3 is used in the methods provided herein. In one embodiment, a mixture of enantiomers of compound 3 is used in the methods provided herein. In one embodiment, a tautomer of compound 3 is used in the methods provided herein. In one embodiment, an isotopologue of compound 3 is used in the methods provided herein. In one embodiment, a pharma- ceutically acceptable salt of compound 3 is used in the methods provided herein.
[0060] Treatment and prevention methods In one embodiment, provided herein is a method of using 2-(2,6-dioxopiperidin-3-yl)-4-((2-fluoro-4-((3-morpholinoazetidin-1-yl)methyl)benzyl)amino)isoindoline-1,3-dione, or an enantiomer, mixture of enantiomers, tautomer, isotopologue, or a pharmaceutically acceptable salt thereof, alone or in combination with obinutuzumab, to treat, prevent, or manage CLL / SLL.
[0061] As used herein and unless otherwise specified, "CLL / SLL" or "CLL and / or SLL" means CLL or SLL, or CLL and SLL. In one embodiment, the method provided herein is for treating, preventing or managing CLL. In one embodiment, the method provided herein is for treating, preventing or managing SLL. In one embodiment, the method provided herein is for treating, preventing or managing CLL and SLL.
[0062] In one embodiment, provided herein is a method of treating CLL / SLL, comprising administering to a subject in need of such treatment a therapeutically effective amount of a compound of the formula: [ka] or a tautomer, isotopologue, or a pharma- ceutically acceptable salt thereof.
[0063] In one embodiment, provided herein is a method of treating CLL / SLL, comprising administering to a subject in need of such treatment a therapeutically effective amount of a compound of the formula: [ka] or a tautomer, isotopologue, or a pharma- ceutically acceptable salt thereof.
[0064] In one embodiment, provided herein is a method of treating CLL / SLL, comprising administering to a subject in need of such treatment a therapeutically effective amount of a compound of the formula: [ka] or an enantiomer, mixture of enantiomers, tautomer, isotopologue, or a pharma- ceutically acceptable salt thereof.
[0065] In one embodiment, provided herein is a method of preventing CLL / SLL, comprising administering to a subject in need thereof a therapeutically effective amount of compound 1, or a tautomer, isotopologue, or pharma- ceutically acceptable salt thereof. In one embodiment, provided herein is a method of preventing CLL / SLL, comprising administering to a subject in need thereof a therapeutically effective amount of compound 2, or a tautomer, isotopologue, or pharma-ceutically acceptable salt thereof. In one embodiment, provided herein is a method of preventing CLL / SLL, comprising administering to a subject in need thereof a therapeutically effective amount of compound 3, or an enantiomer, mixture of enantiomers, tautomer, isotopologue, or pharma-ceutically acceptable salt thereof.
[0066] In one embodiment, provided herein is a method of managing CLL / SLL, comprising administering to a subject in need thereof a therapeutically effective amount of Compound 1, or a tautomer, isotopologue, or pharma- ceutically acceptable salt thereof. In one embodiment, provided herein is a method of managing CLL / SLL, comprising administering to a subject in need thereof a therapeutically effective amount of Compound 2, or a tautomer, isotopologue, or pharma-ceutically acceptable salt thereof. In one embodiment, provided herein is a method of managing CLL / SLL, comprising administering to a subject in need thereof a therapeutically effective amount of Compound 3, or an enantiomer, mixture of enantiomers, tautomer, isotopologue, or pharma-ceutically acceptable salt thereof.
[0067] In one embodiment, the CLL / SLL subject has failed one or more lines of therapy. In one embodiment, the subject has failed at least one prior therapy. In one embodiment, the subject has failed at least two prior therapies. In one embodiment, the subject has been previously treated with an inhibitor of B-cell receptor signaling. In one embodiment, the subject is relapsed or refractory to an inhibitor of B-cell receptor signaling. In one embodiment, the subject has been previously treated with a Bruton's tyrosine kinase (BTK) inhibitor. In one embodiment, the subject is relapsed or refractory to a BTK inhibitor. In one embodiment, the BTK inhibitor is ibrutinib. In one embodiment, the BTK inhibitor is acalabrutinib. In one embodiment, the BTK inhibitor is zanubrutinib. In one embodiment, the BTK inhibitor is tirabrutinib. In one embodiment, the subject has been previously treated with a phosphoinositide 3-kinase (PI3K) inhibitor. In one embodiment, the subject is relapsed or refractory to a PI3K inhibitor. In one embodiment, the PI3K inhibitor is duvelisib. In one embodiment, the PI3K inhibitor is idelalisib. In one embodiment, the subject has been previously treated with venetoclax. In one embodiment, the subject is relapsed or refractory to venetoclax. In one embodiment, the subject has been previously treated with obinutuzumab. In one embodiment, the subject is relapsed or refractory to obinutuzumab.
[0068] In one embodiment, the CLL / SLL is newly diagnosed CLL / SLL. In one embodiment, the CLL / SLL is relapsed or refractory CLL / SLL (R / R CLL / SLL).
[0069] In one embodiment, the CLL is characterized by a mutated IGHV (immunoglobulin heavy chain gene). In one embodiment, the CLL is characterized by a non-mutated IGHV.
[0070] In one embodiment, the CLL is characterized by one or more mutations in TP53 (tumor protein 53). In one embodiment, the CLL is characterized by wild-type TP53.
[0071] In one embodiment, CLL is characterized by one or more cytogenetic abnormalities, such as del(13q), del(11q), del(17p), tri12, t(6;17), del(11q22.3), t(11;14), del(18q) and t(14;19).In one embodiment, CLL is characterized by del(17p).
[0072] In one embodiment, the CLL is characterized by Richter's transformation (also known as Richter's syndrome).
[0073] In one embodiment, the methods provided herein further comprise administering to the subject a therapeutically effective amount of obinutuzumab.
[0074] In one embodiment, a first therapeutic agent provided herein (e.g., an agent such as Compound 1, Compound 2 or Compound 3, or an enantiomer, mixture of enantiomers, tautomer, isotopologue, or pharma- ceutically acceptable salt thereof) is administered prior to (e.g., 5 minutes, 15 minutes, 30 minutes, 45 minutes, 1 hour, 2 hours, 4 hours, 6 hours, 12 hours, 24 hours, 48 hours, 72 hours, 96 hours, 120 hours, 144 hours, 1 week, 2 weeks, 3 weeks, 4 weeks, 5 weeks, 6 weeks, 8 weeks, or 12 weeks prior to) administration of a second therapeutic agent (e.g., obinutuzumab) to a subject.
[0075] In one embodiment, a first therapeutic agent provided herein (e.g., an agent such as Compound 1, Compound 2 or Compound 3, or an enantiomer, mixture of enantiomers, tautomer, isotopologue, or pharma- ceutically acceptable salt thereof) is administered simultaneously with the administration of a second therapeutic agent (e.g., obinutuzumab) to a subject.
[0076] In one embodiment, a first therapeutic agent provided herein (e.g., an agent such as Compound 1, Compound 2, or Compound 3, or an enantiomer, mixture of enantiomers, tautomer, isotopologue, or pharma- ceutically acceptable salt thereof) is administered after (e.g., 5 minutes, 15 minutes, 30 minutes, 45 minutes, 1 hour, 2 hours, 4 hours, 6 hours, 12 hours, 24 hours, 48 hours, 72 hours, 96 hours, 120 hours, 144 hours, 1 week, 2 weeks, 3 weeks, 4 weeks, 5 weeks, 6 weeks, 8 weeks, or 12 weeks) administration of a second therapeutic agent (e.g., obinutuzumab) to a subject.
[0077] In one embodiment, the compound described herein, e.g., Compound 1, Compound 2, or Compound 3, or an enantiomer, mixture of enantiomers, tautomer, isotopologue, or pharma- ceutically acceptable salt thereof, is administered at a dose of about 0.1 mg to about 1.6 mg per day. In one embodiment, the compound is administered at a dose of about 0.1 mg to about 1.2 mg per day. In one embodiment, the compound is administered at a dose of about 0.1 mg to about 0.8 mg per day. In one embodiment, the compound is administered at a dose of about 0.1 mg to about 0.6 mg per day. In one embodiment, the compound is administered at a dose of about 0.1 mg to about 0.4 mg per day. In one embodiment, the compound is administered at a dose of about 0.1 mg to about 0.2 mg per day. In one embodiment, the compound is administered at a dose of about 0.2 mg to about 1.6 mg per day. In one embodiment, the compound is administered at a dose of about 0.2 mg to about 1.2 mg per day. In one embodiment, the compound is administered at a dose of about 0.2 mg to about 0.8 mg per day. In one embodiment, the compound is administered at a dose of about 0.2 mg to about 0.6 mg per day. In one embodiment, the compound is administered at a dose of about 0.2 mg to about 0.4 mg per day. In one embodiment, the compound is administered at a dose of about 0.4 mg to about 1.6 mg per day. In one embodiment, the compound is administered at a dose of about 0.4 mg to about 1.2 mg per day. In one embodiment, the compound is administered at a dose of about 0.4 mg to about 0.8 mg per day. In one embodiment, the compound is administered at a dose of about 0.4 mg to about 0.6 mg per day. In one embodiment, the compound is administered at a dose of about 0.6 mg to about 1.6 mg per day. In one embodiment, the compound is administered at a dose of about 0.6 mg to about 1.2 mg per day. In one embodiment, the compound is administered at a dose of about 0.6 mg to about 0.8 mg per day. In one embodiment, the compound is administered at a dose of about 0.8 mg to about 1.6 mg per day. In one embodiment, the compound is administered at a dose of about 0.8 mg to about 1.2 mg per day.In one embodiment, the compound is administered at a dosage of about 1.2 mg to about 1.6 mg per day.
[0078] In certain embodiments, the compound described herein, for example, Compound 1, Compound 2 or Compound 3, or an enantiomer, a mixture of enantiomers, a tautomer, an isotopologue, or a pharma- ceutically acceptable salt thereof, is administered at a dose of about 0.1 mg, about 0.2 mg, about 0.4 mg, about 0.6 mg, about 0.8 mg, about 1.2 mg, or about 1.6 mg per day. In certain embodiments, the compound is administered at a dose of about 0.1 mg per day. In certain embodiments, the compound is administered at a dose of about 0.2 mg per day. In certain embodiments, the compound is administered at a dose of about 0.4 mg per day. In certain embodiments, the compound is administered at a dose of about 0.6 mg per day. In certain embodiments, the compound is administered at a dose of about 0.8 mg per day. In certain embodiments, the compound is administered at a dose of about 1.2 mg per day. In certain embodiments, the compound is administered at a dose of about 1.6 mg per day.
[0079] In one embodiment, obinutuzumab is administered according to the locally approved label or pharmacy manual for manufacturing, administration and storage information.In one embodiment, obinutuzumab is administered intravenously.In one embodiment, obinutuzumab is administered subcutaneously.In one embodiment, obinutuzumab is administered via intravenous (IV) injection or IV infusion.In one embodiment, obinutuzumab is administered via IV injection.In one embodiment, obinutuzumab is administered via IV infusion.
[0080] In one embodiment, obinutuzumab is administered in an amount according to the physician's judgment. In one embodiment, obinutuzumab is administered per day. In one embodiment, obinutuzumab is administered in a dose of about 75 mg to about 1100 mg per day. In one embodiment, obinutuzumab is administered in a dose of about 75 mg to about 125 mg per day, about 800 mg to about 1000 mg per day, or about 900 mg to about 1100 mg per day. In one embodiment, obinutuzumab is administered in a dose of about 100 mg per day. In one embodiment, obinutuzumab is administered in a dose of about 900 mg per day. In one embodiment, obinutuzumab is administered in a dose of about 1000 mg per day. In one embodiment, obinutuzumab is administered at a dose of about 100 mg on the first day of the first 28-day cycle, about 900 mg on the second day of the first 28-day cycle, and about 1000 mg on the 8th and 15th days of the first 28-day cycle and the first day of the second to sixth 28-day cycles, respectively. In one embodiment, obinutuzumab is administered at a dose of about 1000 mg on the first and 2nd days of the first 28-day cycle, and about 1000 mg on the 8th and 15th days of the first 28-day cycle and the first day of the second to sixth 28-day cycles, respectively. Obinutuzumab may be administered for more than six cycles. In one embodiment, obinutuzumab is administered for the first 28-day cycle as described herein and at about 1000 mg on the first day of the second to twelfth 28-day cycles. In one embodiment, obinutuzumab is administered for an initial 28 day cycle as described herein and is administered at about 1000 mg on the first day of 28 day cycles 2 through 24. In one embodiment, obinutuzumab is administered for an initial 28 day cycle as described herein and is administered at about 1000 mg on the first day of each subsequent 28 day cycle until disease progression.
[0081] In one embodiment, provided herein is a method of treating newly diagnosed CLL / SLL, comprising administering to a subject in need of such treatment a therapeutically effective amount of Compound 1, or a tautomer, isotopologue, or pharma- ceutically acceptable salt thereof. In one embodiment, the method further comprises administering to the subject a therapeutically effective amount of obinutuzumab.
[0082] In one embodiment, provided herein is a method of treating newly diagnosed CLL / SLL, comprising administering to a subject in need of such treatment a therapeutically effective amount of Compound 2, or a tautomer, isotopologue, or pharma- ceutically acceptable salt thereof. In one embodiment, the method further comprises administering to the subject a therapeutically effective amount of obinutuzumab.
[0083] In one embodiment, provided herein is a method of treating newly diagnosed CLL / SLL, comprising administering to a subject in need of such treatment a therapeutically effective amount of compound 3, or an enantiomer, mixture of enantiomers, tautomer, isotopologue, or pharma- ceutically acceptable salt thereof. In one embodiment, the method further comprises administering to the subject a therapeutically effective amount of obinutuzumab.
[0084] In one embodiment, provided herein is a method for preventing newly diagnosed CLL / SLL, comprising administering to a subject in need thereof a therapeutically effective amount of a compound provided herein, such as Compound 1, Compound 2, or Compound 3, or an enantiomer, mixture of enantiomers, tautomer, isotopologue, or pharma- ceutically acceptable salt thereof. In one embodiment, the method further comprises administering to the subject a therapeutically effective amount of obinutuzumab.
[0085] In another embodiment, provided herein is a method of managing newly diagnosed CLL / SLL, comprising administering to a subject in need thereof a therapeutically effective amount of a compound provided herein, e.g., Compound 1, Compound 2, or Compound 3, or an enantiomer, mixture of enantiomers, tautomer, isotopologue, or pharma- ceutically acceptable salt thereof. In one embodiment, the method further comprises administering to the subject a therapeutically effective amount of obinutuzumab.
[0086] In one embodiment, provided herein is a method of treating relapsed or refractory CLL / SLL, comprising administering to a subject in need of such treatment a therapeutically effective amount of Compound 1, or a tautomer, isotopologue, or pharma- ceutically acceptable salt thereof. In one embodiment, the method further comprises administering to the subject a therapeutically effective amount of obinutuzumab.
[0087] In one embodiment, provided herein is a method of treating relapsed or refractory CLL / SLL, comprising administering to a subject in need of such treatment a therapeutically effective amount of Compound 2, or a tautomer, isotopologue, or pharma- ceutically acceptable salt thereof. In one embodiment, the method further comprises administering to the subject a therapeutically effective amount of obinutuzumab.
[0088] In one embodiment, provided herein is a method for treating relapsed or refractory CLL, comprising administering to a subject in need of such treatment a therapeutically effective amount of compound 3, or an enantiomer, a mixture of enantiomers, a tautomer, an isotopologue, or a pharma- ceutically acceptable salt thereof. In one embodiment, the method further comprises administering to the subject a therapeutically effective amount of obinutuzumab.
[0089] In one embodiment, provided herein is a method for preventing relapsed or refractory CLL / SLL, comprising administering to a subject in need thereof a therapeutically effective amount of a compound provided herein, such as Compound 1, Compound 2, or Compound 3, or an enantiomer, mixture of enantiomers, tautomer, isotopologue, or pharma- ceutically acceptable salt thereof. In one embodiment, the method further comprises administering to the subject a therapeutically effective amount of obinutuzumab.
[0090] In another embodiment, provided herein is a method of managing relapsed or refractory CLL / SLL, comprising administering to a subject in need thereof a therapeutically effective amount of a compound provided herein, e.g., Compound 1, Compound 2, or Compound 3, or an enantiomer, mixture of enantiomers, tautomer, isotopologue, or pharma- ceutically acceptable salt thereof. In one embodiment, the method further comprises administering to the subject a therapeutically effective amount of obinutuzumab.
[0091] In another embodiment, provided herein is a method of achieving a complete response, partial response, or stable disease in a patient as determined by the International Workshop on Chronic Lymphocytic Leukemia criteria, comprising administering to a patient with CLL / SLL a therapeutically effective amount of a compound provided herein, e.g., Compound 1, Compound 2, or Compound 3, or an enantiomer, mixture of enantiomers, tautomer, isotopologue, or pharma- ceutically acceptable salt thereof. In one embodiment, minimal residual disease (MRD) detection may be performed in subjects undergoing bone marrow evaluation to confirm complete response (CR). In one embodiment, provided herein is a method of achieving minimal residual disease (MRD) negativity in a patient, comprising administering a therapeutically effective amount of a compound provided herein, e.g., Compound 1, Compound 2, or Compound 3, or an enantiomer, mixture of enantiomers, tautomer, isotopologue, or pharmaceutically acceptable salt thereof, to a patient with CLL / SLL. In one embodiment, MRD negativity is measured in peripheral blood and / or bone marrow. In one embodiment, MRD negativity lasts for at least 3 months. In another embodiment, provided herein is a method of achieving increased overall survival, progression-free survival, event-free survival, progression-free survival, or disease-free survival in a patient, comprising administering a therapeutically effective amount of a compound provided herein, e.g., Compound 1, Compound 2, or Compound 3, or an enantiomer, mixture of enantiomers, tautomer, isotopologue, or pharmaceutically acceptable salt thereof, to a patient with CLL / SLL. In another embodiment, provided herein is a method of achieving increased overall survival in a patient, comprising administering to a patient with CLL / SLL a therapeutically effective amount of a compound provided herein, e.g., Compound 1, Compound 2, or Compound 3, or an enantiomer, mixture of enantiomers, tautomer, isotopologue, or pharma- ceutically acceptable salt thereof.In another embodiment, provided herein is a method of achieving increased progression-free survival in a patient, comprising administering to a patient with CLL / SLL a therapeutically effective amount of a compound provided herein, e.g., Compound 1, Compound 2, or Compound 3, or an enantiomer, mixture of enantiomers, tautomer, isotopologue, or pharma- ceutically acceptable salt thereof. In another embodiment, provided herein is a method of achieving increased event-free survival in a patient, comprising administering to a patient with CLL / SLL a therapeutically effective amount of a compound provided herein, e.g., Compound 1, Compound 2, or Compound 3, or an enantiomer, mixture of enantiomers, tautomer, isotopologue, or pharma-ceutically acceptable salt thereof. In another embodiment, provided herein is a method for achieving an increase in progression-free survival in a patient, comprising administering a therapeutically effective amount of a compound provided herein, such as Compound 1, Compound 2, or Compound 3, or an enantiomer, mixture of enantiomers, tautomer, isotopologue, or pharma- ceutically acceptable salt thereof, to a patient with CLL / SLL. In another embodiment, provided herein is a method for achieving an increase in disease-free survival in a patient, comprising administering a therapeutically effective amount of a compound provided herein, such as Compound 1, Compound 2, or Compound 3, or an enantiomer, mixture of enantiomers, tautomer, isotopologue, or pharma-ceutically acceptable salt thereof, to a patient with CLL / SLL. In one embodiment, the method further comprises administering a therapeutically effective amount of obinutuzumab to the subject.
[0092] The methods provided herein encompass treating patients regardless of their age. In some embodiments, the subject is 18 or older. In other embodiments, the subject is 18, 25, 35, 40, 45, 50, 55, 60, 65, or 70 years old or older. In other embodiments, the subject is under 65 years old. In other embodiments, the subject is 65 years old or older.
[0093] Pharmaceutical Compositions and Routes of Administration The compounds provided herein may be administered orally, topically, or parenterally to a subject in conventional forms of formulations, such as capsules, microcapsules, tablets, granules, powders, troches, pills, suppositories, injections, suspensions, syrups, patches, creams, lotions, ointments, gels, sprays, solutions, and emulsions. Suitable formulations may contain a diluent (e.g., sucrose, starch, mannitol, sorbitol, lactose, glucose, cellulose, talc, calcium phosphate, or calcium carbonate), a binder (e.g., cellulose, methylcellulose, hydroxymethylcellulose, polypropylpyrrolidone, polyvinylpyrrolidone, gelatin, gum arabic, polyethylene glycol, sucrose, or starch), a disintegrant (e.g., starch, carboxymethylcellulose, hydroxypropyl starch, low-substituted hydroxypropylcellulose, sodium bicarbonate, calcium phosphate, or calcium citrate), a lubricant (e.g., magnesium stearate, light anhydrous ketone, calcium phosphate, calcium carbonate ... The pharmaceutical composition may be prepared by a commonly used method using conventional organic or inorganic additives such as glyceryl stearate, talc or sodium lauryl sulfate, flavoring agents (e.g., citric acid, menthol, glycine or orange powder), preservatives (e.g., sodium benzoate, sodium bisulfite, methylparaben or propylparaben), stabilizers (e.g., citric acid, sodium citrate or acetic acid), suspending agents (e.g., methylcellulose, polyvinylpyrrolidone or aluminum stearate), dispersants (e.g., hydroxypropylmethylcellulose), water, and base wax (e.g., cocoa butter, white petrolatum or polyethylene glycol). The effective amount of the compound in the pharmaceutical composition may be at a level that will produce the desired effect in both oral and parenteral administration.
[0094] The compounds provided herein can be administered orally.In one embodiment, when administered orally, the compounds provided herein are administered with food and water.In another embodiment, the compounds provided herein are dispersed in water or fruit juice (e.g., apple juice or orange juice) and administered orally as a solution or suspension.
[0095] Compounds provided herein may also be administered intradermally, intramuscularly, intraperitoneally, through the skin, intravenously, subcutaneously, intranasally, intraepidermally, sublingually, intracerebrally, intravaginally, transdermally, intrarectally, mucosally, by inhalation, or topically to the ear, nose, eye or skin. The method of administration is left to the discretion of the health care practitioner and may depend in part on the site of the medical condition.
[0096] In one embodiment, provided herein is a capsule containing the compound provided herein without additional excipients.In another embodiment, provided herein is a composition comprising an effective amount of the compound provided herein and a pharma- ceutically acceptable excipient, wherein the pharma-ceutically acceptable excipient can include a diluent, a binder, a disintegrant, a lubricant, a glidant, or a mixture thereof.In one embodiment, the composition is a pharmaceutical composition.
[0097] The composition can be in the form of tablets, chewable tablets, capsules, liquids, parenteral solutions, troches, suppositories, suspensions, and the like. The composition can be formulated to contain a daily dose, or a convenient portion of a daily dose, in a dosage unit, which can be a single tablet or capsule, or a convenient volume of liquid. In one embodiment, the liquid is prepared from a water-soluble salt. In general, all compositions are prepared according to known methods in pharmaceutical chemistry. Capsules can be prepared by mixing the compounds provided herein with suitable excipients and filling the appropriate amount of the mixture into capsules. Common excipients include, but are not limited to, inert powdered substances such as many types of starch, powdered cellulose, especially crystalline and microcrystalline cellulose, sugars such as fructose, mannitol and sucrose, cereals and similar edible powders. Capsule fillings can also be prepared by wet granulation or dry granulation.
[0098] In capsule formulations, lubricants may be required to prevent powder from sticking to the pin. Lubricants may be selected from slippery solids such as talc, magnesium and calcium stearates, sodium stearyl fumarate, stearic acid, and hydrogenated vegetable oils. Disintegrants are substances that swell with water, breaking the capsule slugs and releasing the compound. They include starch, clay, cellulose, crospovidone, croscarmellose sodium, sodium starch glycolate, algins and gums. More specifically, corn and potato starch, methylcellulose, agar, bentonite, wood cellulose, powdered natural sponge, cation exchange resins, alginic acid, guar gum, citrus pulp, and carboxymethylcellulose may be used, as well as sodium lauryl sulfate, for example. Lubricants may also be used, including silicon dioxide, talc, and calcium silicate.
[0099] Tablets can be manufactured by direct compression, wet granulation or dry granulation. In addition to the compound, diluents, binders, lubricants and disintegrants are usually included in these preparations. Typical diluents include, for example, various types of starch, lactose, mannitol, kaolin, calcium phosphate or sulfate, inorganic salts such as sodium chloride and powdered sugar. Powdered cellulose derivatives are also useful. Typical tablet binders are substances such as starch, gelatin and sugars such as lactose, fructose, glucose and the like. Natural and synthetic gums are also convenient, including acacia, alginates, methylcellulose, polyvinylpyrrolidone and the like. Polyethylene glycol, ethylcellulose and waxes can also serve as binders.
[0100] In tablet formulations, lubricants may be required to prevent the tablet and punches from sticking in the die. Lubricants may be selected from slippery solids such as talc, magnesium and calcium stearates, sodium stearyl fumarate, stearic acid, and hydrogenated vegetable oils. Tablet disintegrants are substances that swell with water to break the tablet and release the compound. They include starch, clay, cellulose, crospovidone, croscarmellose sodium, sodium starch glycolate, algins and gums. More specifically, corn and potato starch, methylcellulose, agar, bentonite, wood cellulose, powdered natural sponge, cation exchange resins, alginic acid, guar gum, citrus pulp, and carboxymethylcellulose may be used, as well as sodium lauryl sulfate, for example. Lubricants including silicon dioxide, talc, and calcium silicate may also be used. Tablets may be coated with sugar as a flavor and sealant, or with a film-forming protecting agent to modify the dissolution properties of the tablet. The composition may also be formulated as a chewable tablet, for example, by using materials such as mannitol in the formulation.
[0101] When it is desired to administer the compound provided herein as suppository, typical base can be used.Cocoa butter is the traditional suppository base, which can be modified by adding wax to slightly raise its melting point.In particular, the water-miscible suppository base, including polyethylene glycols of various molecular weights, is widely used.
[0102] The effect of the compound provided herein can be delayed or extended by appropriate formulation.For example, the slowly solubilizing pellets of the compound provided herein can be manufactured and incorporated into tablets or capsules, or can be manufactured as sustained release implantable devices.This technique also includes manufacturing pellets with several different dissolution rates and filling capsules with a mixture of the pellets.The tablet or capsule can be coated with a film that resists dissolution for a predictable period of time.Even parenteral formulations can be made long-acting by dissolving or suspending the compound provided herein in oily or emulsified vehicles that allow it to disperse slowly in serum.
[0103] Depending on the disease state to be treated and the condition of the subject, Compound 1, Compound 2 or Compound 3 provided herein, or an enantiomer, a mixture of enantiomers, a tautomer, an isotopologue, or a pharmaceutically acceptable salt thereof, may be administered by oral, parenteral (e.g., intramuscular, intraperitoneal, intravenous, CIV, intratesticular injection or infusion, subcutaneous injection, or implant), inhalation, nasal, vaginal, rectal, sublingual, or topical (e.g., transdermal or topical) routes of administration. Compound 1, Compound 2 or Compound 3 provided herein, or an enantiomer, a mixture of enantiomers, a tautomer, an isotopologue, or a pharmaceutically acceptable salt thereof, may be formulated into a suitable dosage unit, either alone or together with pharmaceutically acceptable excipients, carriers, adjuvants, and vehicles appropriate for each administration route.
[0104] In one embodiment, Compound 1, Compound 2, or Compound 3 provided herein, or an enantiomer, a mixture of enantiomers, a tautomer, an isotopologue, or a pharma- ceutically acceptable salt thereof, is administered orally. In another embodiment, Compound 1, Compound 2, or Compound 3 provided herein, or an enantiomer, a mixture of enantiomers, a tautomer, an isotopologue, or a pharma-ceutically acceptable salt thereof, is administered parenterally. In yet another embodiment, Compound 1, Compound 2, or Compound 3 provided herein, or an enantiomer, a mixture of enantiomers, a tautomer, an isotopologue, or a pharma-ceutically acceptable salt thereof, is administered intravenously.
[0105] Compound 1, Compound 2 or Compound 3 provided herein, or an enantiomer, mixture of enantiomers, tautomers, isotopologues, or pharma- ceutically acceptable salt thereof, can be delivered in a single dose, e.g., a single bolus injection, or an oral capsule, tablet, or pill, or can be delivered over time, e.g., as a continuous infusion over time or as divided boluses over time. Compounds as described herein can be administered repeatedly as necessary, e.g., until the patient experiences stable disease or regression, or until the patient experiences disease progression or unacceptable toxicity.
[0106] Compound 1, compound 2 or compound 3 provided herein, or its enantiomer, mixture of enantiomers, tautomer, isotopologue, or pharmaceutically acceptable salt, can be administered once a day (QD) or divided into multiple daily doses, such as twice a day (BID), three times a day (TID), and four times a day (QID). In addition, administration can be continuous (i.e., daily or every day), or intermittent, for example, in cycles (i.e., with drug-free rest days for days, weeks, or months). As used herein, the term "daily" means that a therapeutic compound, such as compound 1, compound 2 or compound 3 provided herein, or its enantiomer, mixture of enantiomers, tautomer, isotopologue, or pharmaceutically acceptable salt, is administered, for example, once or more times a day for a period of time. The term "continuous" is intended to mean that a therapeutic compound, such as Compound 1, Compound 2 or Compound 3, or an enantiomer, a mixture of enantiomers, a tautomer, an isotopologue, or a pharma- ceutically acceptable salt thereof, provided herein, is administered daily for an uninterrupted period of at least 7 days to 52 weeks. The term "intermittent" or "intermittent" as used herein is intended to mean stopping and starting at either regular or irregular intervals. For example, intermittent administration of Compound 1, Compound 2 or Compound 3, or an enantiomer, a mixture of enantiomers, a tautomer, an isotopologue, or a pharma-ceutically acceptable salt thereof, provided herein, can be administered 1-6 days per week, in cycles (daily administration for 2-8 consecutive weeks followed by a rest period of up to 1 week without administration), or every other day. The term "cycling" as used herein is intended to mean that a therapeutic compound provided herein, such as Compound 1, Compound 2 or Compound 3, or an enantiomer, mixture of enantiomers, tautomer, isotopologue, or pharma- ceutically acceptable salt thereof, is administered daily or continuously, but with rest periods.
[0107] In some embodiments, the frequency of administration ranges from approximately daily dose to approximately monthly dose.In one embodiment, administration is once a day, twice a day, three times a day, four times a day, once every other day, twice a week, once every week, once every two weeks, once every three weeks, or once every four weeks.In one embodiment, compound 1, compound 2, or compound 3 provided herein, or its enantiomer, mixture of enantiomers, tautomer, isotopologue, or pharmaceutically acceptable salt, is administered once a day.In another embodiment, compound 1, compound 2, or compound 3 provided herein, or its enantiomer, mixture of enantiomers, tautomer, isotopologue, or pharmaceutically acceptable salt, is administered twice a day. In yet another embodiment, Compound 1, Compound 2, or Compound 3 provided herein, or an enantiomer, mixture of enantiomers, tautomer, isotopologue, or pharma- ceutically acceptable salt thereof, is administered three times per day. In yet another embodiment, Compound 1, Compound 2, or Compound 3 provided herein, or an enantiomer, mixture of enantiomers, tautomer, isotopologue, or pharma- ceutically acceptable salt thereof, is administered four times per day.
[0108] In one embodiment, the methods provided herein comprise administering a therapeutically effective amount of Compound 1, Compound 2, or Compound 3 in one or more seven-day treatment cycles. In another embodiment, the methods provided herein comprise administering a therapeutically effective amount of Compound 1, Compound 2, or Compound 3 on days 1 through 5 of a seven-day cycle. In another embodiment, the methods provided herein comprise administering a therapeutically effective amount of Compound 1, Compound 2, or Compound 3 on days 1 through 3 of a seven-day cycle.
[0109] In one embodiment, the methods provided herein comprise administering a therapeutically effective amount of Compound 1, Compound 2, or Compound 3 in one or more 14-day treatment cycles. In another embodiment, the methods provided herein comprise administering a therapeutically effective amount of Compound 1, Compound 2, or Compound 3 from day 1 through day 7 of a 14-day cycle. In another embodiment, the methods provided herein comprise administering a therapeutically effective amount of Compound 1, Compound 2, or Compound 3 from day 1 through day 10 of a 14-day cycle. In another embodiment, the methods provided herein comprise administering a therapeutically effective amount of Compound 1, Compound 2, or Compound 3 from day 1 through day 5 of a 14-day cycle.
[0110] In one embodiment, the methods provided herein include administering a therapeutically effective amount of Compound 1, Compound 2, or Compound 3 in one or more 28-day treatment cycles. In another embodiment, the methods provided herein include administering a therapeutically effective amount of Compound 1, Compound 2, or Compound 3 from day 1 through day 21 of a 28-day cycle. In another embodiment, the methods provided herein include administering a therapeutically effective amount of Compound 1, Compound 2, or Compound 3 from day 1 through day 5, day 8 through day 12, day 15 through day 19, and day 22 through day 26 of a 28-day cycle. In another embodiment, the methods provided herein include administering a therapeutically effective amount of Compound 1, Compound 2, or Compound 3 from day 1 through day 10, and day 15 through day 24 of a 28-day cycle. In another embodiment, the methods provided herein include administering a therapeutically effective amount of Compound 1, Compound 2, or Compound 3 from day 1 through day 7, and day 15 through day 21 of a 28-day cycle. In another embodiment, the methods provided herein comprise administering a therapeutically effective amount of Compound 1, Compound 2 or Compound 3 from day 1 through day 14 of a 28-day cycle.
[0111] In one embodiment, compound 1, compound 2 or compound 3 is administered once a day for 5 days, followed by 2 days of rest. In one embodiment, compound 1, compound 2 or compound 3 is administered once a day for 3 days, followed by 4 days of rest. In one embodiment, compound 1, compound 2 or compound 3 is administered once a day for 5 days, followed by 9 days of rest. In one embodiment, compound 1, compound 2 or compound 3 is administered once a day for 7 days, followed by 7 days of rest. In one embodiment, compound 1, compound 2 or compound 3 is administered once a day for 10 days, followed by 4 days of rest. In one embodiment, compound 1, compound 2 or compound 3 is administered once a day for 21 days, followed by 7 days of rest. In one embodiment, compound 1, compound 2 or compound 3 is administered once a day for 14 days, followed by 14 days of rest.
[0112] In one embodiment, the treatment comprises administering a therapeutically effective amount of obinutuzumab in one or more treatment cycles. In one embodiment, obinutuzumab is administered twice every 7 days. In one embodiment, obinutuzumab is administered once every week. In one embodiment, obinutuzumab is administered once every 4 weeks. In one embodiment, obinutuzumab is administered on days 1, 2, 8, and 15 of a first 28 day cycle and on the first day of a second through sixth 28 day cycle. In one embodiment, obinutuzumab is administered on the first day of a second through a twelfth 28 day cycle. In one embodiment, obinutuzumab is administered on the first day of a second through a twenty-fourth 28 day cycle. In one embodiment, obinutuzumab is administered on the first day of subsequent 28 day cycles until disease progression.
[0113] In one embodiment, obinutuzumab is administered at a dose of about 100 mg on the first day of the first 28-day cycle, about 900 mg on the second day of the first 28-day cycle, and about 1000 mg on each of the 8th and 15th days of the first 28-day cycle. In one embodiment, obinutuzumab is administered at a dose of about 1000 mg on the first and second days of the first 28-day cycle, and about 1000 mg on each of the 8th and 15th days of the first 28-day cycle. In one embodiment, obinutuzumab is administered at a dose of about 1000 mg on the first day of the second to sixth 28-day cycles. In one embodiment, obinutuzumab is administered at a dose of about 1000 mg on the first day of the second to twelfth 28-day cycles. In one embodiment, obinutuzumab is administered at about 1000 mg on the first day of 28-day cycles 2 through 24. In one embodiment, obinutuzumab is administered at about 1000 mg on the first day of each subsequent 28-day cycle until disease progression. In one embodiment, obinutuzumab is administered at about 1000 mg on the first 28-day cycle at least one week prior to initiating administration of a compound provided herein, e.g., Compound 1.
[0114] In one embodiment, the subject receives the first dose of Compound 1 at least one week before Compound 1 is first administered. In one embodiment, the subject receives the first dose of obinutuzumab one week before the first dose of Compound 1. In one embodiment, the subject receives the first dose of obinutuzumab 13 days before the first dose of Compound 1. In one embodiment, the subject receives the first dose of obinutuzumab 14 days before the first dose of Compound 1. In one embodiment, the subject receives the first dose of obinutuzumab 14 days before the first dose of Compound 1, and receives subsequent doses of obinutuzumab 13 and 7 days before the first dose of Compound 1. In one embodiment, the first dose of obinutuzumab is at least 1000 mg. In one embodiment, the first dose of obinutuzumab is about 1000 mg. The first dose of obinutuzumab can be a single dose administered on one day, or a combined dose administered on multiple days.In one embodiment, before the subject receives the first dose of compound 1 on the 15th day of the first 28-day cycle, the subject is administered obinutuzumab at a dose of about 100mg on the first day of the first 28-day cycle, about 900mg on the second day of the first 28-day cycle, and about 1000mg on the 8th day of the first 28-day cycle.In one embodiment, before the subject receives the first dose of compound 1 on the 15th day of the first 28-day cycle, the subject is administered obinutuzumab at a dose of about 1000mg on the first and second days of the first 28-day cycle, and about 1000mg on the 8th day of the first 28-day cycle.
[0115] In one embodiment, the methods provided herein include administering a first dose of obinutuzumab at least one week prior to administering a first dose of Compound 1. In one embodiment, the methods provided herein include administering a first dose of obinutuzumab at least one week prior to administering a first dose of Compound 1. In one embodiment, the method provided herein comprises administering the first dose of obinutuzumab 13 days before administering the first dose of compound 1. In one embodiment, the method provided herein comprises administering the first dose of obinutuzumab 14 days before administering the first dose of compound 1. In one embodiment, the method provided herein comprises administering the first dose of obinutuzumab 14 days before administering the first dose of compound 1, and administering subsequent doses of obinutuzumab 13 and 7 days before administering the first dose of compound 1. In one embodiment, the first dose of obinutuzumab is at least 1000 mg. In one embodiment, the first dose of obinutuzumab is about 1000 mg. The first dose of obinutuzumab can be a single dose administered on one day or a combined dose administered on multiple days. In one embodiment, the methods provided herein include administering obinutuzumab at a dose of about 100 mg on day 1 of the first 28 day cycle, about 900 mg on day 2 of the first 28 day cycle, and about 1000 mg on day 8 of the first 28 day cycle, prior to administering the first dose of compound 1 on day 15 of the first 28 day cycle. In one embodiment, the methods provided herein include administering obinutuzumab at a dose of about 1000 mg on both days 1 and 2 of the first 28 day cycle, and about 1000 mg on day 8 of the first 28 day cycle, prior to administering the first dose of compound 1 on day 15 of the first 28 day cycle.
[0116] In one embodiment, the methods provided herein include (i) administering obinutuzumab at a dose of about 100 mg on day 1, about 900 mg on day 2, and about 1000 mg on each of days 8 and 15 of an initial 28-day cycle ("Cycle 1"), followed by administration of about 1000 mg on day 1 of a subsequent 28-day cycle ("Cycle 2" etc.); and (ii) administering Compound 1, starting on day 15 of cycle 1, once daily for 7 days, followed by 7 days of rest.
[0117] In one embodiment, the methods provided herein include (i) administering obinutuzumab at a dose of about 100 mg on day 1, about 900 mg on day 2, and about 1000 mg on each of days 8 and 15 of an initial 28-day cycle ("Cycle 1"), followed by administration of about 1000 mg on day 1 of a subsequent 28-day cycle ("Cycle 2"); and (ii) administering Compound 1, starting on day 15 of cycle 1, once daily for 5 days, followed by 9 days of rest.
[0118] In one embodiment, the methods provided herein include (i) administering obinutuzumab at a dose of about 100 mg on day 1, about 900 mg on day 2, and about 1000 mg on each of days 8 and 15 of an initial 28-day cycle ("Cycle 1"), followed by administration of about 1000 mg on day 1 of a subsequent 28-day cycle ("Cycle 2" etc.); and (ii) administering Compound 1, starting on day 15 of cycle 1, once daily for 14 days, followed by 14 days of rest.
[0119] In one embodiment, the methods provided herein include (i) administering obinutuzumab at a dose of about 100 mg on day 1, about 900 mg on day 2, and about 1000 mg on each of days 8 and 15 of an initial 28-day cycle ("Cycle 1"), followed by administration of about 1000 mg on day 1 of a subsequent 28-day cycle ("Cycle 2"); and (ii) administering Compound 1, starting on day 15 of cycle 1, once daily for 21 days, followed by 7 days of rest.
[0120] Any treatment cycle described herein may be repeated at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30 or more cycles. In certain examples, a treatment cycle as described herein includes 1 to about 24 cycles, about 2 to about 16 cycles, or about 2 to about 4 cycles. In certain examples, a treatment cycle as described herein includes 1 to about 4 cycles. In some embodiments, a therapeutically effective amount of Compound 1, Compound 2 or Compound 3, and / or obinutuzumab is administered in 1 to 13 28-day cycles (e.g., about 1 year). In some embodiments, a therapeutically effective amount of Compound 1, Compound 2 or Compound 3, and / or obinutuzumab is administered in 1-24 28-day cycles (e.g., about 2 years).In certain instances, the cycle therapy is not limited in number of cycles, and the therapy is continued until disease progression.In certain instances, the cycle may include varying the duration of administration and / or rest periods as described herein.
[0121] Working Example The following examples are presented for illustrative purposes, but are not limiting. Compounds are named using the automatic name generating tool provided by ChemBiodraw Ultra (Cambridgesoft), which systematically names chemical structures and supports the Cahn-Ingold-Prelog rules for stereochemistry. Those skilled in the art can modify the procedures shown in the illustrative examples to obtain the desired products.
[0122] Abbreviations used: [Table 5]
[0123] Example 1: Synthesis of (S)-2-(2,6-dioxopiperidin-3-yl)-4-((2-fluoro-4-((3-morpholinoazetidin-1-yl)methyl)benzyl)amino)isoindoline-1,3-dione (Compound 1) [ka] (S)-2-(2,6-dioxopiperidin-3-yl)-4-((2-fluoro-4-(hydroxymethyl)benzyl)amino)isoindoline-1,3-dione: A suspension of (S)-4-amino-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione (5.00 g, 18.3 mmol) and 2-fluoro-4-(hydroxymethyl)benzaldehyde (2.82 g, 18.30 mmol) in 2:1 dioxane-MeOH (75 mL) was cooled to 0° C. and mixed with B 10 H 14 (4.92 g, 40.3 mmol) was added in portions over 5 min. The reaction flask was fitted with a septum and needle vent (pressure) and stirred vigorously for 10 min. The mixture was allowed to reach ambient temperature and stirred for 3 h. The mixture was concentrated and the residue was purified by silica gel chromatography (0-10% MeOH-DCM) to give (S)-2-(2,6-dioxopiperidin-3-yl)-4-((2-fluoro-4-(hydroxymethyl)benzyl)amino)isoindoline-1,3-dione (4.23 g, 56%) as a yellow solid. LCMS (ESI) m / z 411.8[M+H] +
[0124] (S)-4-((4-(chloromethyl)-2-fluorobenzyl)amino)-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione A solution of (S)-2-(2,6-dioxopiperidin-3-yl)-4-((2-fluoro-4-(hydroxymethyl)benzyl)amino)isoindoline-1,3-dione (0.727 g, 1.77 mmol) in dry NMP (6 mL) was cooled to 0° C., and methanesulfonyl chloride (0.275 mL, 3.35 mmol) and DIEA (0.617 mL, 3.53 mmol) were added successively. The reaction mixture was allowed to reach ambient temperature and stirred for 18 h. The reaction mixture was slowly added to HO (60 mL) cooled to 0° C. with vigorous mixing. The resulting suspension was filtered, and the solid was collected and washed with HO and EtO. The solid was dissolved in EtOAc and the solution was dried over MgSO4, filtered and concentrated to give (S)-4-((4-(chloromethyl)-2-fluorobenzyl)amino)-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione (0.600 g, 79%) as a yellow solid. LCMS (ESI) m / z 430.0 [M+H] +
[0125] (S)-2-(2,6-dioxopiperidin-3-yl)-4-((2-fluoro-4-((3-morpholinoazetidin-1-yl)methyl)benzyl)amino)isoindoline-1,3-dione To a solution of (S)-4-((4-(chloromethyl)-2-fluorobenzyl)amino)-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione (300 mg, 0.698 mmol) in dry DMSO (1.0 mL) was added 4-(azetidin-3-yl)morpholine hydrochloride (125 mg, 0.698 mmol) and DIEA (0.122 mL, 0.698 mmol). The reaction mixture was stirred at ambient temperature for 18 h and diluted with DMSO (1 mL). The solution was purified by chiral reverse phase chromatography to give (S)-2-(2,6-dioxopiperidin-3-yl)-4-((2-fluoro-4-((3-morpholinoazetidin-1-yl)methyl)benzyl)amino)isoindoline-1,3-dione (89 mg, 24%, 97% ee). LCMS (ESI) m / z 536.2 [M+H] +
[0126] Example 2: Synthesis of (R)-2-(2,6-dioxopiperidin-3-yl)-4-((2-fluoro-4-((3-morpholinoazetidin-1-yl)methyl)benzyl)amino)isoindoline-1,3-dione (Compound 2) [ka] In addition, the product was subjected to chiral reverse phase chromatography as described in Example 1 to obtain (R)-2-(2,6-dioxopiperidin-3-yl)-4-((2-fluoro-4-((3-morpholinoazetidin-1-yl)methyl)benzyl)amino)isoindoline-1,3-dione (16 mg, 97% ee). LCMS (ESI) m / z 535.6 [M+H] +
[0127] Example 3: Synthesis of 2-(2,6-dioxopiperidin-3-yl)-4-((2-fluoro-4-((3-morpholinoazetidin-1-yl)methyl)benzyl)amino)isoindoline-1,3-dione (Compound 3) [ka] (4-Bromo-3-fluoro-phenyl)methanol: A solution of 4-bromo-3-fluoro-benzoic acid (15.0 g, 68.5 mmol) in THF (150 mL) was cooled to 0° C. and borane·dimethylsulfide complex (13.7 mL, 137 mmol, 10 M in THF) was added dropwise under nitrogen atmosphere. The cooling bath was removed and the mixture was stirred at ambient temperature for 12 h. The mixture was cooled to 0° C., quenched with MeOH (50 mL) and poured into water (30 mL). The mixture was concentrated under vacuum and the remaining aqueous mixture was diluted with ethyl acetate (150 mL) and water (150 mL) and stirred for 15 min. The organic phase was removed and the aqueous phase was extracted with ethyl acetate (150 mL×2). The organic fractions were combined, dried over anhydrous sodium sulfate, filtered and concentrated under vacuum. The residue was purified by silica gel column chromatography (2-10% ethyl acetate in petroleum ether) to give (4-bromo-3-fluoro-phenyl)methanol (13.1 g, 93.3% yield) as a colorless liquid. LCMS (ESI) m / z 187.0 [MH-18 + ]; 1 H NMR (400MHz, CDCl3) δ ppm 7.54-7.45(m,1H), 7.14(d,J=9.2Hz,1H), 7.00(d,J=7.9Hz,1H), 4.64(d,J=4.6Hz,2H), 2.20(brs,1H)
[0128] (4-Bromo-3-fluoro-phenyl)methoxy-tert-butyl-dimethyl-silane: A solution of (4-bromo-3-fluoro-phenyl)methanol (13.1 g, 63.9 mmol) and imidazole (12.2 g, 179 mmol) in DMF (150 mL) was cooled to 0° C. and tert-butylchlorodimethylsilane (14.4 g, 95.8 mmol) was added. The cooling bath was removed and the mixture was stirred at ambient temperature for 16 h. The reaction was poured into cold water (30 mL), diluted with ethyl acetate (100 mL) and water (100 mL) and stirred for 15 min. The organic phase was removed and the aqueous phase was extracted with ethyl acetate (150 mL×2). The organic fractions were combined, washed with saturated NaCl (50 mL×2), dried over anhydrous sodium sulfate, filtered and concentrated under vacuum. The residue was purified by silica gel column chromatography (0-10% ethyl acetate in petroleum ether) to give (4-bromo-3-fluoro-phenyl)methoxy-tert-butyl-dimethyl-silane (18.6 g, 91.2% yield) as a colorless liquid. 1 H NMR (400MHz, CDCl3) δ ppm 7.49(dd,J=7.1, 8.1Hz,1H), 7.18-7.08(m,1H), 7.01-6.92(m,1H), 4.69(s,2H), 0.96(s,9H), 0.12(s,6H)
[0129] 4-[[tert-Butyl(dimethyl)silyl]oxymethyl]-2-fluoro-benzaldehyde: Under nitrogen atmosphere, a solution of (4-bromo-3-fluoro-phenyl)methoxy-tert-butyl-dimethyl-silane (18.6 g, 58.3 mmol) in THF (150 mL) was cooled to -78°C and n-BuLi (25.6 mL, 64.0 mmol, 2.5 M in hexane) was added dropwise. The mixture was stirred at -78°C for 5 min and DMF (5.83 mL, 75.7 mmol) was added. The mixture was stirred at -78°C for 2 h and allowed to warm to ambient temperature. The reaction mixture was cooled to 0°C and quenched with saturated ammonium chloride (60 mL) and water (30 mL). The mixture was extracted with ethyl acetate (2x150 mL) and the combined extracts were dried over sodium sulfate, filtered and concentrated. The residue was purified by silica gel column chromatography (0-2% ethyl acetate in petroleum ether) to give 4-[[tert-butyl(dimethyl)silyl]oxymethyl]-2-fluoro-benzaldehyde (11.5 g, 73.5% yield) as a yellow liquid. MS(ESI) m / z: 269.1[M+1] +
[0130] 3-((4-(((tert-butyldimethylsilyl)oxy)methyl)-2-fluorobenzyl)amino)phthalic acid: A solution of 4-[[tert-butyl(dimethyl)silyl]oxymethyl]-2-fluoro-benzaldehyde (7.50 g, 27.9 mmol) and 3-aminophthalic acid (5.06 g, 27.9 mmol) in 1:10 acetic acid-MeOH (110 mL) was stirred at 25° C. for 30 minutes and cooled to 0° C. Borane 2-methylpyridine complex (4.48 g, 41.9 mmol) was added and the mixture was allowed to reach ambient temperature. The mixture was stirred at ambient temperature for 16 hours and the mixture was concentrated under reduced pressure. The residue was diluted with water (25 mL) and ethyl acetate (25 mL) and stirred for 15 minutes. The organic layer was removed and the aqueous layer was extracted with ethyl acetate (30 mL×2). The organic fractions were combined, dried over anhydrous sodium sulfate, filtered and concentrated. The residue was purified by silica gel column chromatography (2-5% ethyl acetate in petroleum ether) to give 3-((4-(((tert-butyldimethylsilyl)oxy)methyl)-2-fluorobenzyl)amino)phthalic acid (9.90 g, 81.8% yield) as a white solid. LCMS (ESI) m / z: 434.1 [M+1] +
[0131] 4-((4-(((tert-butyldimethylsilyl)oxy)methyl)-2-fluorobenzyl)amino)-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione: A solution of 3-((4-(((tert-butyldimethylsilyl)oxy)methyl)-2-fluorobenzyl)amino)phthalic acid (11.8 g, 27.2 mmol) and 3-aminopiperidine-2,6-dione hydrochloride (6.72 g, 40.8 mmol) in pyridine (150 mL) was stirred at 120° C. under nitrogen atmosphere for 12 h. The mixture was concentrated under reduced pressure and the residue was purified by silica gel column chromatography (2-5% ethyl acetate in petroleum ether) to give 4-((4-(((tert-butyldimethylsilyl)oxy)methyl)-2-fluorobenzyl)amino)-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione (9.90 g, 69.2% yield) as a yellow solid. LCMS (ESI) m / z: 526.2 [M+1] +
[0132] 2-(2,6-dioxopiperidin-3-yl)-4-((2-fluoro-4-(hydroxymethyl)benzyl)amino)isoindoline-1,3-dione: To a solution of 4-((4(((tert-butyldimethylsilyl)oxy)methyl)-2-fluorobenzyl)amino)-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione (9.90 g, 18.8 mmol) in THF (100 mL) was added concentrated sulfuric acid (20.0 mL, 368 mmol) and the mixture was stirred at ambient temperature for 12 hours. The mixture was concentrated under vacuum and the residue was treated with 1:5 ethyl acetate-petroleum ether (20 mL). The resulting suspension was stirred for 30 minutes and filtered. The solid was collected, washed with 1:5 ethyl acetate-petroleum ether and dried under vacuum to give 2-(2,6-dioxopiperidin-3-yl)-4-((2-fluoro-4-(hydroxymethyl)benzyl)amino)isoindoline-1,3-dione (6.58 g, 85.2% yield) as a yellow solid. MS(ESI) m / z:412.0[M+1] + ; 1 H NMR (400MHz, DMSO-d6) δ ppm 11.12(s,1H), 7.54(dd,J=7.3, 8.4Hz,1H), 7.33(t,J=7.8Hz,1H), 7.16-7.07(m,3H), 7.05(d,J=7.0Hz,1H), 6.99(d,J=8.5Hz,1H), 5.33-5.2 5(m,1H), 5.07(dd,J=5.3, 12.9Hz,1H), 4.59(d,J=6.3Hz,2H), 4.47(d,J=5.8Hz,2H), 2.95-2.84(m,1H), 2.65-2.52(m,2H), 2.09-2.01(m,1H)
[0133] 4-((4-(chloromethyl)-2-fluorobenzyl)amino)-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione: A solution of 2-(2,6-dioxopiperidin-3-yl)-4-((2-fluoro-4-(hydroxymethyl)benzyl)amino)isoindoline-1,3-dione (6.58 g, 16.0 mmol) in dichloromethane (200 mL) was cooled to 0° C. and thionyl chloride (20.0 mL, 276 mmol) was added dropwise. After the addition was complete, the cooling bath was removed and the reaction mixture was stirred at ambient temperature for 2 hours. The mixture was concentrated under vacuum and the residue was purified by silica gel column chromatography (1.00-1.25% MeOH in dichloromethane) to give 4-((4-(chloromethyl)-2-fluorobenzyl)amino)-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione (3.80 g, 55.4% yield) as a yellow solid. LCMS(ESI) m / z:430.0[M+1] + ; 1 H NMR (400MHz, DMSO-d6) δ ppm 11.12(s,1H), 7.54(dd,J=7.3, 8.4 Hz,1H), 7.38(t,J=7.9Hz,1H), 7.32(dd,J=1.5, 11.0Hz,1H), 7.24(dd,J=1.6, 7.8Hz,1H), 7.16(t,J=6.3Hz,1H), 7.06(d,J=6.9Hz,1H), 6.98 (d,J=8.5Hz,1H), 5.08(dd,J=5.3, 12.9Hz,1H), 4.74(s,2H), 4.63(d,J=6.3Hz,2H), 2.95-2.85(m,1H), 2.66-2.53(m,2H), 2.09-2.02(m,1H)
[0134] 2-(2,6-dioxopiperidin-3-yl)-4-((2-fluoro-4-((3-morpholinoazetidin-1-yl)methyl)benzyl)amino)isoindoline-1,3-dione: To a solution of 4-((4-(chloromethyl)-2-fluorobenzyl)amino)-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione (215 mg, 0.500 mmol) (prepared as provided herein) and 4-(azetidin-3-yl)morpholine hydrochloride (107 mg, 0.600 mmol) in dry DMSO (1.7 mL) was added DIEA (262 μL, 1.50 mmol) and the mixture was stirred at ambient temperature for 48 hours. The reaction mixture was diluted with 20% formic acid in DMSO (2.5 mL) and filtered through a membrane syringe filter (0.45 μm nylon). The solution was purified using standard methods to give 2-(2,6-dioxopiperidin-3-yl)-4-((2-fluoro-4-((3-morpholinoazetidin-1-yl)methyl)benzyl)amino)isoindoline-1,3-dione (173 mg, 64.6% yield). LCMS (ESI) m / z 536.2 [M+H] +
[0135] Example 4: Cell proliferation and viability assays using CLL cell lines Below are examples of cell-based assays that can be used to measure the antiproliferative and apoptotic effects of the compounds described herein using exemplary CLL cell lines (Table 3). The in vitro growth inhibitory activity of compound 1 described herein was evaluated using a 384-well flow cytometry assay.
[0136] Table 3. CLL cell lines [Table 6] RPMI = RPMI 1640; FBS = fetal bovine serum; NEAA = non-essential amino acids; IMDM = Iscove's modified Dulbecco's medium
[0137] Cell lines were plated in 384-well flat-bottom plates under the conditions shown in Table 3 and incubated with increasing concentrations of compounds ranging from 0.00015 to 10 μM or with dimethyl sulfoxide (DMSO) control. The final concentration of DMSO was 0.1% (v / v). After 120 hours of incubation with compound 1 or DMSO, cell number and cell death were analyzed by flow cytometry (Attune®, Thermo Fisher) using Annexin V and the live cell impermeable DNA dye, DRAQ7. Phosphatidylserine translocates from the inner to the outer layer of the plasma membrane early in apoptosis, and Annexin V binds to exposed phosphatidylserine found on the surface of apoptotic cells. The vital dye DRAQ7 is excluded by intact live cells and stains only cells that have died as a result of apoptosis or necrosis.
[0138] Next, Flow Jo Flow cytometry data analysis was performed using v10 software to measure the number of live cells (Annexin V and DRAQ7 double negative stained cells) and the percentage of apoptotic cells (Annexin V positive cells) in each condition. The number of live cells at every concentration was normalized to the DMSO control (considered to be 100% viable cells) and the percentage of viable cells remaining after treatment was calculated and graphed using GraphPad Prism 7.03. IC50 (50% inhibitory concentration) and Emax (maximum efficacy achieved) values were then calculated by nonlinear regression curve fitting using log(inhibitor) vs. normalized response-variable slope analysis in GraphPad Prism 7.03. Area under the curve (AUC) was calculated by area under the curve analysis in GraphPad Prism 7.03. Similarly, for apoptosis analysis, the percentage of apoptosis compared to DMSO, combining both "early" (Annexin V positive and DRAQ7 negative) and "late" apoptotic (Annexin V and DRAQ7 positive) cell gates, was graphed using GraphPad Prism 7.03. AUC from apoptosis curves, EC 50(the concentration of compound that produces a half-maximal apoptotic response) and Y max Values (maximal percentage of apoptosis achieved) were calculated by area under the curve analysis and non-linear regression curve fitting using log(agonist) vs. normalized response-variable slope analysis in GraphPad Prism 7.03.
[0139] As shown in Table 4, dose-response growth curves of Compound 1 for a panel of CLL cell lines and nonlinear curve fit regression were used to determine the IC50, AUC, and Emax% of viable cells (Emax for viable fraction varies between 100 at low doses and 0 at high doses, which corresponds to inhibition of all viable cells), and dose-response apoptosis curves of Compound 1 were used to determine the EC 50 , AUC, and Y for Apoptosis % max (Y about apoptosis max (varying between 0 at low doses and 100 at high doses, which corresponds to the death of all cells) was determined.
[0140] Compound 1 was found to have antiproliferative activity and / or apoptotic effects in CLL cell lines (Table 4). Table 4. Antiproliferative and / or apoptotic effects of compound 1 in CLL cell lines [Table 7] AUC=area under the curve;IC 50 =50% inhibitory concentration (μM); E max = maximal efficacy to achieve tumor cell elimination, expressed as a percentage of remaining tumor cells; EC 50 Y = concentration of compound that elicits half-maximal apoptotic response (μM); max = Calculated percentage of control at maximum concentration of compound 1
[0141] Example 5: Cell proliferation and survival assays for B-cell CLL patient cells The following are examples of cell-based assays that can be used to measure the anti-proliferative activity and apoptotic effects of the compounds described herein, using exemplary CLL patient cells: The effect of Compound 1 on CLL B cell survival and apoptosis was evaluated using an ex vivo model.
[0142] CLL is a clonal CD5 resistant to apoptosis + CD19 + The effect of compound 1 on CLL B cell survival and apoptosis was assessed using an ex vivo model in which primary CLL cells from patient-derived blood were stimulated with 10% fetal bovine serum (FBS), 5 ng / mL recombinant human interleukin-4 (rhIL-4), 10 ng / mL recombinant human interleukin-10 (rhIL-10) and cultured with fibroblasts expressing surface CD154 (CD40L). The percentage of cells stained with Annexin V and / or DRAQ-7 was measured by flow cytometry assays after 3, 6 or 10 days of incubation with vehicle control or with increasing concentrations of compound 1 ranging from 0.001 to 1 μM. 70%-95% of CD5 + CD19 + Peripheral blood mononuclear cells (PBMCs) from CLL patients (Table 5) containing tumor cells were plated on a monolayer of fibroblasts expressing CD154 in 24-well plates at 0.8x10 patient cells per well. 6 Cells were grown at a density of 1x10 and cultured in RPMI 1640 medium supplemented with 10% FBS, 5 ng / mL rhIL-4, and 10 ng / mL rhIL-10 and treated with vehicle control (0.1% DMSO) or increasing concentrations of Compound 1 ranging from 0.001 to 1 μM. After treatment, the number of viable or apoptotic cells was determined using flow cytometry analysis.
[0143] Table 5. Characteristics of the CLL samples used [Table 8] IGHV status refers to somatic mutations in the IGHV genes of CLL cells compared to the germline gene sequence. Nd = not performed / unknown; tri = trisomy; del = deletion; t = translocation.
[0144] After 3, 6 or 10 days of compound treatment, cells were incubated with Annexin V and the vital far-red fluorescent DNA dye DRAQ-7, which stains only the nuclei of dead and permeabilized cells, to capture phosphatidylserine externalization as a consequence of disruption of lipid asymmetry in the cell cytoplasm, a well-characterized event in apoptosis, and analyzed by flow cytometry (Attune®, Thermo Fisher). Analysis was performed using v10 and the percentage of viable cells (Annexin V and DRAQ-7 double negative stained cells) was measured and graphed using GraphPad Prism 7.03 software. The number of viable cells in all conditions was normalized to the DMSO control (considered to be 100% viable cells) and the percentage of viable cells remaining after treatment was calculated. IC50 (50% inhibitory concentration) and Emax (maximum efficacy achieved to eliminate tumor cells) values were then calculated by nonlinear regression curve fitting using log(inhibitor) vs. normalized response-variable slope analysis on GraphPad Prism 7.03. Area under the curve (AUC) values for viable cell count over time were calculated by area under the curve analysis on GraphPad Prism 7.03 (Table 6).
[0145] A strong dose-dependent inhibition of CLL cell proliferation was observed for compound 1 in all CLL patient samples evaluated, with concentrations of compound 1 resulting in a 50% inhibition of proliferation (IC50) between 0.0001 and 0.003 μM (Table 6). Sensitivity to compound 1 was independent of IGHV mutation status and other chromosomal characteristics.
[0146] Table 6. Antiproliferative effect of compound 1 on ex vivo cultures of cells from CLL patients. [Table 9] AUC=area under the curve;IC 50 =50% inhibitory concentration (μM); E max = maximum efficacy to achieve tumor cell elimination, expressed as a percentage of remaining tumor cells; Pt = patient
[0147] Example 6: Antiproliferative effect of the combination of Compound 1 and obinutuzumab in B-cell CLL patient cells Obinutuzumab (GA101) is a humanized glycoengineered type 2 antibody targeting CD20. Obinutuzumab showed superior efficacy by inducing direct cell death and enhancing antibody-dependent cellular cytotoxicity compared to rituximab. The effect of treatment with compound 1 in combination with obinutuzumab on CLL B cell proliferation and survival was evaluated using ex vivo experiments in which primary CLL cells from patient-derived blood were stimulated to grow in 96-well plate format with 10% fetal bovine serum (FBS), 5 ng / mL recombinant human interferon-4 (rhIL-4), 10 ng / mL recombinant human interferon-10 (rhIL-10) and co-cultured with fibroblasts expressing surface CD154 (CD40L).
[0148] 52%-86% CD5 + CD19 + Peripheral blood mononuclear cells (PBMCs) from CLL patients (Table 7) containing tumor cells were cultured in 96-well plates with 0.09x10 6 The monolayers were cultured at a density of 0.09-0.1x10 cells / well in RPMI 1640 medium supplemented with 10% FBS, 5ng / mL rhIL-4, and 10ng / mL rhIL-10. 6 Cells were cultured at a density of 100 cells / well. Cells were treated with vehicle control (0.1% DMSO), increasing concentrations of compound 1 ranging from 0.001 to 1 μM, and GA101 at concentrations ranging from 8 ng / mL to 5 μg / mL across all different concentrations of compound 1. After 144 hours of treatment with both agents, the number of viable or apoptotic tumor cells was determined using flow cytometry analysis.
[0149] Tumor cell numbers were assessed by staining PBMCs from patients in each condition with tumor cell surface markers CD5 & CD19 along with a live / dead fixative dye to exclude dead cells, followed by intracellular staining for caspase 3 antibody to identify apoptotic cells, measured by flow cytometry (Attune NxT, Thermo Fisher). The number of tumor viable cells for each condition was calculated by normalizing to precision counting beads added to each sample.
[0150] Table 7. Characteristics of the CLL samples used [Table 10]
[0151] The number of viable tumor cells was then normalized to the DMSO control (considered 100% viable) and the percentage of viable cells remaining after treatment was calculated. The normalized percentage of tumor cells was then represented as a heatmap using GraphPad Prism 8.00 to show the degree of tumor toxicity for each of the combinations (Figure 1). Based on the data shown in Figure 1, calculations of synergistic / additive effects were performed using the HSA and Bliss Independence Model. Either synergistic or additive effects were observed in three patients (pts 11, 12 & 13) out of the four patient samples tested.
[0152] For apoptosis analysis, both "early" (caspase 3 positive and live-dead fixed dye negative) and "late" apoptotic (caspase 3 and live-dead fixed dye positive) cell gates were combined, baseline DMSO values were subtracted, and the percentage of apoptosis was graphed using GraphPad Prism 8.0.0.0. Ymax (maximum percentage of apoptosis achieved) values from the apoptosis curves were nonlinearly regression curve-fitted using log(agonist) vs. normalized response-variable slope analysis, and the maximum was identified on GraphPad Prism 8.0.0 (Table 8). Obinutuzumab alone induced apoptosis and moderately enhanced the apoptosis-inducing ability of compound 1.
[0153] Table 8. Maximal apoptotic effect of compound 1 in combination with obinutuzumab [Table 11]
[0154] Example 7: Phase I Clinical Trials A Phase 1b, multi-center, open-label study will be conducted to determine the safety, pharmacokinetics, and preliminary efficacy of compound 1 in combination with obinutuzumab in subjects with relapsed or refractory chronic lymphocytic leukemia / small lymphocytic lymphoma (R / R CLL / SLL).
[0155] OBJECTIVES: The primary objective of this study is to determine the safety and tolerability of compound 1 in combination with obinutuzumab in subjects with R / R CLL / SLL. Another primary objective is to define the maximum tolerated dose (MTD) and / or recommended phase 2 dose (RP2D) of compound 1 in combination with obinutuzumab in subjects with R / R CLL / SLL.
[0156] The secondary objectives are to evaluate the preliminary efficacy of Compound 1 in combination with obinutuzumab in subjects with R / R CLL / SLL and to determine the pharmacokinetics (PK) of Compound 1 when used in combination with obinutuzumab in subjects with R / R CLL / SLL.
[0157] Study Design: This is an open-label, Phase 1b study to evaluate the safety, PK, and preliminary efficacy of Compound 1 when administered orally in combination with obinutuzumab in subjects with R / R CLL / SLL. All eligible subjects must be relapsed or refractory to at least two lines of prior CLL / SLL therapy, including a Bruton's tyrosine kinase (BTK) inhibitor. All subjects must be treatment eligible at the time of study entry. The study will be conducted in two parts: Part A (dose escalation) and Part B (dose expansion). Dose escalation (Part A) will evaluate the safety, tolerability, and PK of escalating doses of Compound 1 administered intravenously in combination with obinutuzumab to determine the MTD and RP2D of Compound 1 when administered in combination with obinutuzumab. Compound 1 will be administered orally once daily on the planned dosing days. If the starting dose / schedule is not tolerated, a lower dose or a less strenuous schedule may be considered. All treatments will be administered until disease progression, unacceptable toxicity, death, or subject / investigator decision to discontinue, for a total of up to 24 cycles of treatment.
[0158] After dose escalation (Part A) is completed, a selected expansion cohort of approximately 20 evaluable subjects (Part B) will receive Compound 1 in combination with obinutuzumab.
[0159] The total daily dose to be administered to the next dose cohort will be determined mathematically, taking into account the available safety, PK and PD data collected.
[0160] In Part B, based on examination of safety, PK, and PD data from Part A, dose expansion may occur at the MTD established in the dose escalation phase or at another tolerated dosing regimen.
[0161] Best overall response will be determined by iwCLL defined criteria (Table 1). Response will be assessed by the investigator. One or more dosing regimens may be selected for cohort expansion.
[0162] Study Population: Study subjects will include men and women aged 18 years or older with R / R CLL / SLL who have failed prior therapy as detailed in the inclusion / exclusion criteria.
[0163] Inclusion Criteria: Subjects must meet the following criteria to be enrolled in this study: 1. At the time of signing the Informed Consent Form (ICF), the control > I am 18 years old. 2. Subjects must understand and willingly sign the ICF before any study-related assessments / manipulations are performed. 3. Subject is willing and able to comply with the study visit schedule and other protocol requirements. 4. Subjects must have a documented diagnosis of CLL / SLL requiring treatment (iwCLL Guidelines for the Diagnosis and Treatment of CLL) (Tables 1 and 2). In addition: a. The presence of clinically measurable disease as determined by at least one of the factors listed: - Nodular lesions, measured with a longest dimension (LD) > 1.5 cm, and the longest perpendicular dimension (LPD) is > 1.0 cm, or - In the spleen, the longest vertical dimension (LVD) is measured > 14 cm with at least 2 cm of expansion, or - LVD measured in the liver> 20 cm with a minimum expansion of 2 cm, or - Peripheral blood B lymphocyte count >5000 / μL 5. Subjects must meet criteria for relapsed and / or refractory disease to at least two prior lines of therapy according to iwCLL guidelines. 6. All eligible subjects must have relapsed after or be refractory to at least two prior lines of therapy, one of which must include an approved BTK inhibitor. 7. Subjects have an Eastern Cooperative Oncology Group (ECOG) performance status of 0-2 (Table 2). 8. Subject must meet the following laboratory parameters: a. Absolute neutrophil count (ANC) is > 1,500 cells / mm 3 or secondary to bone marrow damage due to disease. > 1,000 cells / mm 3 It is. b. The number of platelets is > 100,000 cells / mm 3 (100x10 9 / L) or secondary to bone marrow damage due to disease. > 50,000 cells / mm 3 (50x10 9 / L). c. Serum aspartate transaminase (AST / SGOT) or alanine transaminase (ALT / SGPT) <3.0 x upper limit of normal (ULN). d. Serum bilirubin <1.5 x ULN, except in cases due to Gilbert syndrome. e. Calculated creatinine clearance > The flow rate is 60 mL / min. 9. Subjects must agree to regular pregnancy testing and pregnancy risk management plans during the study and after completion of study treatment. This applies even if the subject practices true abstinence from heterosexual contact. Females of childbearing potential (FCBP) are women who: 1) have had menarche at some point; 2) have not had a hysterectomy or bilateral salpingectomy; or 3) have not had natural menstrual closure for at least 24 consecutive months (i.e., have had menses at some point during the past 24 consecutive months) (amenorrhea following cancer therapy does not preclude the possibility of pregnancy); Prior to starting study therapy, subjects must have two negative pregnancy tests, as confirmed by the investigator, and must agree to continue pregnancy testing throughout the study and after study therapy has ended. This applies even if the subject practices true abstinence from contact with the opposite sex. b. Commit to true abstinence from contact with the opposite sex (this must be confirmed on a monthly basis and must be documented in source) OR agree to be able to use and adhere to, without interruption, two reliable forms of contraception as defined in the PPP and provided to the subject at the time of informed consent, for 28 days prior to starting Compound 1, during study therapy (including during any dose interruptions), and for 28 days after discontinuation of study therapy, or for 18 months after the last dose of obinutuzumab, whichever is the last of the following:
[0164] A male subject, even if he has had a successful vasectomy, must agree to practice true abstinence (this must be verified on a monthly basis) or use condoms during sexual contact with pregnant or reproductive potential women while participating in the study, while discontinued, and for at least 3 months after discontinuation of study drug, or longer as necessary for each compound and / or by local regulations. (True abstinence may be acceptable if this is consistent with the subject's preferred usual lifestyle. Periodic abstinence (e.g., calendar, ovulation induction, symptomatic, postovulatory methods) and discontinuation are not acceptable methods of contraception.)
[0165] Exclusion Criteria: Subjects will be excluded from enrollment if any of the following are present: 1. The subject has any significant medical condition, laboratory abnormality, or psychiatric illness that would prevent the subject from participating in the study. 2. The subject has any condition, including the presence of laboratory abnormalities, that would place the subject at unacceptable risk if he / she were to participate in the study. 3. The subject has any condition that impairs their ability to interpret data from the study. 4. Have had a prior allogeneic stem cell transplant (SCT) / bone marrow transplant within 12 months of signing the ICF. > Subjects who underwent allogeneic SCT within the prior 12 months may also be eligible, provided they have no ongoing graft-versus-host disease (GVHD) and are not currently undergoing immunosuppressive therapy. 5. Has ongoing or active infection requiring parenteral antibiotics. 6. Uncontrolled intercurrent illnesses, including but not limited to: a. Uncontrolled diabetes mellitus; target glycemic levels for diabetic subjects should follow established guidelines (e.g., International Diabetes Federation, the European Diabetes Working Party guidelines, and the American Diabetes Association) taking into account the subject's age, comorbidities, life expectancy, and functional status. > In older subjects ( 10 years or older), the target glycosylated hemoglobin A1C (HbA1C) should be <7.0%. > For subjects aged 70 years or older or with a life expectancy of <10 years, the target HbA1C should be <8.0%. Consultation with an endocrinologist is recommended to determine if diabetes is optimally controlled. Subjects with a stable HbA1C higher than the suggested target may be enrolled in consultation with a medical monitor. b. Chronic symptomatic congestive heart failure (Class III or IV according to the New York Heart Association Classification for Heart Disease); c. Active central nervous system involvement documented by cerebrospinal fluid cytology or imaging; d. Uncontrolled autoimmune hemolytic anemia or thrombocytopenia; e. Have other concurrent serious and / or uncontrolled concomitant medical conditions that may pose an unacceptable safety risk or impair compliance with the protocol. 7. The subject is Compound 1 < Have received prior systemic anti-cancer therapy (approved or investigational) within 5 half-lives or 4 weeks prior to initiating treatment with Compound 1 (whichever is shorter). 8. The subject begins treatment with Compound 1. < Have received a prior CAR-T or other T-cell targeted therapy (approved or investigational) within the past 4 weeks. 9. The subject begins treatment with Compound 1. <Prior therapy with a CRBN modulator (e.g., lenalidomide, avadomide / CC-122, pomalidomide) within the past 4 weeks. 10. Life expectancy < Have a 2-year history of another malignancy or require a therapy that would confound the test results. This does not include: Basal cell carcinoma of the skin; b. Squamous cell carcinoma of the skin; c. Cervical intraepithelial neoplasia; d. Breast intraepithelial carcinoma; e. Bladder carcinoma in situ; f. Incidental histologic findings of prostate cancer (tumor, node, metastasis [TNM] stage of T1a or T1b) 11. Known seropositivity for or history of active viral infection with human immunodeficiency virus (HIV) or hepatitis B or C viruses (HBV, HCV). Screening for hepatitis B is mandatory for all patients (HBsAg and anti-HBc). Patients with active hepatitis B should not be treated with obinutuzumab. If the patient is a carrier, they should be referred to a specialist before initiating treatment (see PI or SmPC). Subjects who are positive for anti-HBc and / or anti-HBs but negative for HBsAg and HBV DNA may be treated in consultation with a hepatologist. 12. Peripheral neuropathy > It is grade 2. 13. Use of systemic corticosteroids at doses greater than 20 mg / day prednisolone equivalent. 14. Receiving medications that have a high potential to cause QT prolongation or ventricular arrhythmias (torsades de pointes). Subjects on chronic medications in this category may also be enrolled after consideration with medical monitoring if changing these medications is not in the patient's best medical interest. 15. History of hypersensitivity to immunomodulatory imide drugs (IMiDs®) (lenalidomide, pomalidomide, thalidomide). 16. Have cardiac dysfunction or clinically significant cardiac disease, including any of the following: a. LVEF <45% as measured by MUGA scan or ECHO; b. Complete left bundle branch block or bifascicular block; c. Congenital long QT syndrome; d. Persistent or uncontrolled ventricular arrhythmias or atrial fibrillation; e. QTcF >470 ms on screening ECG (average of triplicate recordings); f. Start with compound 1 < unstable angina or myocardial infarction occurring within 6 months; g. Uncontrolled congestive heart failure or uncontrolled hypertension 17. Persistent diarrhea or malabsorption despite medical management > NCI CTCAE grade 2. 18. Active disease (i.e., Richter's syndrome); Subjects with Richter's syndrome who have signed the ICF >2 years ago are eligible. 19. Known acute or chronic pancreatitis. 20. Pregnant or breastfeeding women. 21. Hypersensitivity to obinutuzumab or any of its excipients.
[0166] Length of the Study: The entire study is expected to last approximately four years. The study will consist of three phases: Screening, Treatment, and Follow-up. During the Screening Phase, subjects will be evaluated to determine their eligibility for up to 28 consecutive days from the time they sign the informed consent until their first dose.
[0167] Subjects who are accepted into the study will enter the treatment phase, during which they will receive the investigational product [IP] at a prescribed dose and schedule until their underlying CLL / SLL disease progresses or the subject discontinues IP treatment due to unacceptable toxicity or other reasons.
[0168] The follow-up phase begins with discontinuation of study treatment. Subjects will visit as soon as possible at the end of treatment, when IP is discontinued, and 28 days after the last dose of IP. All subjects who discontinue for reasons other than disease progression, consent withdrawal, or death will be contacted every 90 days from the date of the 28-day follow-up visit to obtain information on symptoms of their disease and on the type and start date of subsequent anti-cancer therapy. Efficacy assessments (including clinical tests, laboratory tests, and CT scans) will continue until PD is documented or subsequent anti-CLL therapy is initiated.
[0169] The end of the study will be defined as the later of the date of the last subject's last visit to complete post-treatment follow-up or the date of receipt of the last data point from the last subject required for the primary, secondary and / or exploratory analyses as pre-specified in the protocol.
[0170] Study Treatment: Subjects will begin treatment upon confirmation of eligibility.
[0171] Obinutuzumab is administered by intravenous infusion. Obinutuzumab is administered on days 1, 2, 8, and 15 of cycle 1. Obinutuzumab is administered at a dose of 100 mg on day 1 of cycle 1, 900 mg on day 2 of cycle 1, and 1000 mg on each of day 8 of cycle 1 and day 15 of cycle 1. The doses of obinutuzumab on days 1 and 2 of cycle 1 may be adjusted according to institutional practice as long as the combined dose is 1000 mg. Obinutuzumab is administered at a dose of 1000 mg on days 1 of cycles 2-6.
[0172] All active subjects with clinical benefit in the opinion of the investigator may continue to receive study treatment with compound 1 for up to 24 cycles or until discontinued for progressive disease (PD), unacceptable toxicity, or other reasons, whichever occurs first. In the event that compound 1 is discontinued prior to obinutuzumab, obinutuzumab will also be discontinued. In the event that obinutuzumab is permanently discontinued, compound 1 may be continued. Subjects who achieve sustained minimal residual disease (MRD) negativity (in both peripheral blood and bone marrow) for a minimum period of 3 months have the option to discontinue study treatment; study treatment in these subjects may be resumed upon MRD positivity.
[0173] Summary of key efficacy evaluations: Efficacy evaluations included: 1) overall response rate (ORR) [complete response (CR), complete response with incomplete bone marrow recovery (CRi), nodal partial response (nPR), partial response (PR), partial response with lymphocytosis (PRL)] as assessed by the iwCLL 2018 guidelines (Tables 1 and 2); 2) clinical laboratory assessments; 3) tumor imaging assessments (CT scans); 4) bone marrow aspirate / biopsy at 1; 5) ECOG performance status; and 6) B symptom assessment.
[0174] Summary of Key Safety Assessments: Safety assessments included: 1) adverse events (AEs) using NCI CTCAE v5, unless otherwise specified, to select AEs; 2) vital signs; 3) physical examination; 4) concomitant medications and maneuvers; 5) electrocardiogram (ECG); 6) clinical laboratory assessments (including hematology and clinical chemistry assessments with renal and hepatic function assessments); 7) pregnancy test; and 8) left ventricular ejection fraction (LVEF).
[0175] Pharmacokinetic evaluation summary: Blood samples will be collected following an intensive and sparse sampling methodology to characterize the PK of compound 1 when administered in combination with obinutuzumab. Obinutuzumab serum concentrations will be measured at specific time points. Trends in the exposure-response relationships of compound 1 and markers of efficacy, safety, and biological response will also be evaluated.
[0176] Example 8: Phase I Clinical Trials A Phase 1b, multi-center, open-label study will be conducted to determine the safety, pharmacokinetics, and preliminary efficacy of compound 1 in combination with obinutuzumab in subjects with relapsed or refractory chronic lymphocytic leukemia / small lymphocytic lymphoma (R / R CLL / SLL).
[0177] OBJECTIVES: The primary objective of the study is to determine the safety and tolerability of compound 1 in combination with obinutuzumab in subjects with R / R CLL / SLL. Another primary objective is to define the maximum tolerated dose (MTD) and / or recommended phase 2 dose (RP2D) of compound 1 in combination with obinutuzumab in subjects with R / R CLL / SLL.
[0178] The secondary objectives are to evaluate the preliminary efficacy of Compound 1 in combination with obinutuzumab in subjects with R / R CLL / SLL and to determine the pharmacokinetics (PK) of Compound 1 when used in combination with obinutuzumab in subjects with R / R CLL / SLL.
[0179] Study Design: This is an open-label, Phase 1b study to evaluate the safety, PK, and preliminary efficacy of Compound 1 when administered orally in combination with obinutuzumab in subjects with R / R CLL / SLL. All eligible subjects must be relapsed or refractory to at least two lines of prior CLL / SLL therapy, including an inhibitor of B-cell receptor signaling (an approved Bruton's tyrosine kinase (BTK) inhibitor [BTKi] or phosphoinositide 3-kinase inhibitor "PI3Ki") or venetoclax. Prior therapy with an obinutuzumab-containing regimen will be permitted.
[0180] All subjects must be treatment eligible at the time of study entry. The study will be conducted in two parts: Part A (dose escalation) and Part B (dose expansion). Dose escalation (Part A) will evaluate the safety, tolerability and PK of increasing doses of Compound 1 administered intravenously in combination with obinutuzumab to determine the MTD and RP2D of Compound 1 when administered in combination with obinutuzumab. Approximately 25-30 subjects may be enrolled in Part A. The actual number will depend on the number of schedules / dose levels required to determine the MTD or RP2D. Compound 1 will be administered orally once daily on the scheduled dosing days. The starting dose / schedule of Compound 1 will be 0.2 mg / day for 7 consecutive days (beginning on day 15 of cycle 1), followed by 7 days off study drug every 14 days in each of the 28-day cycles (7 / 14 day schedule). If the starting dose / schedule is not tolerated, a lower dose or a less strenuous schedule may be considered. All treatments will be administered for a total of up to 24 cycles of treatment or 2 years until disease progression, unacceptable toxicity, death, or subject / investigator decision to discontinue.
[0181] After dose escalation (Part A) is completed, a selected expansion cohort of approximately 20 evaluable subjects (Part B) will be administered Compound 1 in combination with obinutuzumab. Evaluation of safety / tolerability, PK and preliminary efficacy of the expansion cohort of Compound 1 further combined with other CLL / SLL agents of interest (e.g., rituximab; ibrutinib; venetoclax; or other agents) may begin in parallel in Part B. For the study, enrollment is occurring worldwide, including the United States (US), Europe, and / or Canada. Additional countries and regions may be added for Part B and / or Part A.
[0182] A Bayesian logistic regression model (BLRM) (Neuenschwander B et al., Statistics in medicine 2008, 27: 2420-39) with excess dose control (EWOC) (Babb J et al., Statistics in medicine 1998, 17: 1103-20) is utilized to help determine dose escalation / de-escalation of Compound 1.
[0183] Subjects evaluable for dose-limiting toxicity (DLT) are defined as those who 1) receive at least 75% of the scheduled doses of Compound 1 and obinutuzumab without experiencing a DLT between Day 15 of Cycle 1 and Day 14 of Cycle 2, or 2) experience a DLT after receiving at least one dose of Compound 1, or a fraction thereof, between Day 15 of Cycle 1 and Day 14 of Cycle 2.
[0184] Alternative Compound 1 dosing schedules (e.g., 5 / 14 days, 14 / 28 days, or 21 / 28 days) may be considered based on review of available clinical safety, PK, and PD data. If a new schedule is considered, the total dose planned in the cycle should not exceed the total dose of any previously tolerated schedule or currently tolerated expansion thereof, and the maximum daily dose should not exceed a 100% increase of the previously tolerated daily dose in any schedule. The BLRM may be adjusted as a covariate for each schedule, although different schedules may be considered.
[0185] The first cohort will be treated under a 7 / 14 day regimen with a daily dose of 0.2 mg. If toxicity is observed at the starting dose, dose level-1 (DL-1) of 0.1 mg / day may be considered.
[0186] The total daily dose that can then be administered to the dosing cohort is determined computationally, taking into account the available safety, PK and PD data collected, or is the dose recommended by BLRM (Neuenschwander B et al., Statistics in medicine 2008, 27: 2420-39) using the excess dose control (EWOC) (Babb J et al., Statistics in medicine 1998, 17: 1103-20) method. The planned dose levels are 0.1 mg, 0.2 mg, 0.4 mg, 0.6 mg, 0.8 mg, 1.2 mg and 1.6 mg. However, it is possible that the actual dose levels selected for the trial may differ from the prescriptive dose levels based on reviewing the safety, PK, PD and efficacy data.
[0187] The DLT rate for the MTD of Compound 1 in combination with obinutuzumab is 25%; the minimum sample size per dosing cohort will be 3 subjects. The total number of subjects required to determine the MTD of Compound 1 in combination with obinutuzumab is estimated to be approximately 25-30 subjects.
[0188] In Part B, based on examination of safety, PK, and PD data from Part A, dose expansion may occur at the MTD established in the dose escalation phase or at another tolerated dosing regimen.
[0189] Best overall response will be determined by the criteria defined by the International Workshop on Chronic Lymphocytic Leukemia (iwCLL) (Table 1). Response will be assessed by the investigator. One or more dosing regimens may be selected for cohort expansion.
[0190] Study Population: Study subjects will include men and women aged 18 years or older with R / R CLL / SLL who have failed prior therapy as detailed in the inclusion / exclusion criteria.
[0191] Inclusion Criteria: Subjects must meet the following criteria to be enrolled in this study: 1. At the time of signing the Informed Consent Form (ICF), the control > I am 18 years old. 2. Subjects must understand and willingly sign the ICF before any study-related assessments / manipulations are performed. 3. Subject is willing and able to comply with the study visit schedule and other protocol requirements. 4. Subjects must have a documented diagnosis of CLL / SLL requiring treatment (iwCLL Guidelines for the Diagnosis and Treatment of CLL) (Tables 1 and 2). In addition: a. The presence of clinically measurable disease as determined by at least one of the factors listed: - Nodular lesions, measured with a longest dimension (LD) > 1.5 cm, and the longest perpendicular dimension (LPD) is > 1.0 cm, or - In the spleen, the longest vertical dimension (LVD) is measured > 14 cm with at least 2 cm of expansion, or - LVD measured in the liver > 20 cm with a minimum expansion of 2 cm, or - Peripheral blood B lymphocyte count >5000 / μL 5. Subjects must meet criteria for relapsed and / or refractory disease to at least two prior lines of therapy according to iwCLL guidelines. 6. All eligible subjects must have relapsed after or be refractory to at least two lines of prior therapy, one of which must contain an inhibitor of B-cell receptor signaling (approved BTK inhibitor i or PI3Ki) or venetoclax. Prior therapy with an obinutuzumab-containing regimen is permitted. 7. Subjects have an Eastern Cooperative Oncology Group (ECOG) performance status of 0-2 (Table 2). 8. Subject must meet the following laboratory parameters: a. Absolute neutrophil count (ANC) is > 1,500 cells / mm 3 or secondary to bone marrow damage due to disease. > 1,000 cells / mm 3 It is. b. The number of platelets is > 100,000 cells / mm 3 (100x10 9 / L) or secondary to bone marrow damage due to disease. > 50,000 cells / mm 3 (50x10 9 / L). c. Serum aspartate transaminase (AST / SGOT) or alanine transaminase (ALT / SGPT) <3.0 x upper limit of normal (ULN). d. Serum bilirubin <1.5 x ULN, except in cases due to Gilbert syndrome. e. Estimated serum creatinine clearance is determined using the Cockcroft-Gault equation or directly by a 24-hour urine collection method. > The flow rate is 60 mL / min. 9. Subjects must agree to regular pregnancy testing and pregnancy risk management plans during the study and after completion of study treatment. This applies even if the subject practices true abstinence from heterosexual contact. Females of childbearing potential (FCBP) are women who: 1) have had menarche at some point; 2) have not had a hysterectomy or bilateral salpingectomy; or 3) have not had natural menstrual closure for at least 24 consecutive months (i.e., have had menses at some point during the past 24 consecutive months) (amenorrhea following cancer therapy does not preclude the possibility of pregnancy); a. Prior to starting study therapy, two negative pregnancy tests must be obtained, as confirmed by the Investigator. A pregnancy screening test (urine or serum) is performed on day 14, day 1, one day prior to cycle 1, with a second confirmatory test (serum) performed within 24 hours of day 1 of cycle 1. In addition, a pregnancy test must be performed 24 hours prior to day 15 of cycle 1 prior to administration of Compound 1. The woman must agree to continue pregnancy testing throughout the study period, even after study therapy has ended. This applies even if the subject practices true abstinence from contact with the opposite sex. b. Commit to true abstinence from contact with the opposite sex (this must be confirmed on a monthly basis and must be documented in source) OR agree to be able to use and adhere to, without interruption, two reliable forms of contraception as defined in the PPP and provided to the subject at the time of informed consent, for 28 days prior to starting Compound 1, during study therapy (including during any dose interruptions), and for 28 days after discontinuation of study therapy, or for 18 months after the last dose of obinutuzumab, whichever is the last of the following: c. Pregnancy must be avoided for 28 days after the last dose of Compound 1. d. Must agree to refrain from breast-feeding while receiving Compound 1 and for 28 days after discontinuation. e. Agree to refrain from donating eggs while receiving Compound 1 and for 30 days after discontinuation.
[0192] A male subject must agree to practice true abstinence (this must be verified on a monthly basis) or use condoms during sexual contact with pregnant or reproductive potential women while participating in the study, while taking medication, and for at least 3 months after discontinuation of study drug, or longer as necessary for each compound and / or depending on local regulations, even if he has had a successful vasectomy. Men must agree to refrain from donating semen or sperm while taking Compound 1 and for 90 days after discontinuation (true abstinence may be acceptable if this is consistent with the subject's preferred usual lifestyle. Periodic abstinence (e.g., calendar, ovulation induction, symptomatic, postovulatory methods) and discontinuation are not acceptable methods of contraception.)
[0193] Exclusion Criteria: Subjects will be excluded from enrollment if any of the following are present: 1. The subject has any significant medical condition, laboratory abnormality, or psychiatric illness that would prevent the subject from participating in the study. 2. The subject has any condition, including the presence of laboratory abnormalities, that places the subject at unacceptable risk if he / she were to participate in the study. 3. The subject has any condition that impairs their ability to interpret data from the study. 4. Have had a prior allogeneic stem cell transplant (SCT) / bone marrow transplant within 12 months of signing the ICF. > Subjects who underwent allogeneic SCT within the prior 12 months may also be eligible, provided they have no ongoing graft-versus-host disease (GVHD) and are not currently undergoing immunosuppressive therapy. 5. Has ongoing or active infection requiring parenteral antibiotics. 6. Uncontrolled intercurrent illnesses, including but not limited to: a. Chronic symptomatic congestive heart failure (Class III or IV according to the New York Heart Association Classification for Heart Disease); b. Active central nervous system involvement documented by cerebrospinal fluid cytology or imaging; c. Uncontrolled / active autoimmune hemolytic anemia or thrombocytopenia; d. Have other concurrent serious and / or uncontrolled concomitant medical conditions that may pose an unacceptable safety risk or impair compliance with the protocol. 7. The subject is Compound 1 < Have received prior systemic anti-cancer therapy (approved or investigational) within 5 half-lives or 4 weeks prior to initiating treatment with Compound 1 (whichever is shorter). 8. The subject begins treatment with Compound 1. < Have received a prior CAR-T or other T-cell targeted therapy (approved or investigational) within the past 4 weeks. 9. The subject begins treatment with Compound 1. < Prior therapy with a CRBN modulator (e.g., lenalidomide, avadomide / CC-122, pomalidomide) within the past 4 weeks. 10. Life expectancy < Have a 2-year history of another malignancy or require a therapy that would confound the test results. This does not include: Basal cell carcinoma of the skin; b. Squamous cell carcinoma of the skin; c. Cervical intraepithelial neoplasia; d. Breast intraepithelial carcinoma; e. Bladder carcinoma in situ; f. Incidental histologic findings of prostate cancer (Tumor, Node, Metastasis [TNM] stage of T1a or T1b) 11. Known seropositivity for or history of active viral infection with human immunodeficiency virus (HIV) or hepatitis B or C virus (HBV, HCV). Screening for hepatitis B is mandatory for all patients (HBsAg and anti-HBc). Patients with active hepatitis B should not be treated with obinutuzumab. If the patient is a carrier, they should be referred to a specialist before starting treatment (see Gazyva PI or Gazyvaro SmPC). Subjects who are positive for anti-HBc and / or anti-HBs but negative for HBsAg and HBV DNA may be treated in consultation with a hepatologist. This does not encompass false positive results for patients receiving intravenous immunoglobulin (IVIG). 12. Peripheral neuropathy > It is grade 2. 13. The subject is undergoing treatment with chronic systemic immunosuppressive therapy or corticosteroids (e.g., prednisolone or its equivalent at a dose not exceeding 10 mg / day within the past 14 days) or is subject to clinically significant GVHD. Acknowledge stable use of inhaled corticosteroids; b. Use of topical steroids for ongoing cutaneous or ocular GVHD is permitted. 14. History of hypersensitivity to lenalidomide, pomalidomide, or thalidomide. 15. Have cardiac dysfunction or clinically significant cardiac disease, including any of the following: a. LVEF <45% as measured by MUGA scan or ECHO; b. Complete left bundle branch block or bifascicular block; c. Congenital long QT syndrome; d. Persistent or uncontrolled ventricular arrhythmias or atrial fibrillation; e. QTcF >470 ms on screening ECG (average of triplicate recordings); f. Start with compound 1 < unstable angina or myocardial infarction occurring within 6 months; 16. Persistent diarrhea or malabsorption despite medical management > NCI CTCAE grade 2. 17. Active disease (i.e., Richter's syndrome); Subjects with Richter's syndrome who have signed the ICF >2 years ago are eligible. 18. Known acute or chronic pancreatitis. 19. Pregnant or breastfeeding women. 20. Hypersensitivity to obinutuzumab or any of its excipients. 21. Strong CYP3A4 / 5 modulators are being co-administered.
[0194] Length of Study: The entire study is expected to last approximately 4 years. The study will consist of three phases / periods: Screening, Treatment, and Follow-up. During the Screening Phase, subjects will be evaluated to determine their eligibility for up to 28 consecutive days from the time they sign the informed consent until their first dose.
[0195] Subjects who are accepted into the study will enter the treatment phase, during which they will receive the investigational product [IP] at a prescribed dose and schedule until their underlying CLL / SLL disease progresses or the subject discontinues IP treatment due to unacceptable toxicity or other reasons.
[0196] The follow-up phase begins with discontinuation of study treatment. Subjects will visit as soon as possible at the end of treatment, when IP is discontinued, and 28 days after the last dose of IP. All subjects who discontinue for reasons other than disease progression, consent withdrawal, or death will be contacted every 90 days from the date of the 28-day follow-up visit to obtain information on symptoms of their disease and on the type and start date of subsequent anti-cancer therapy. Efficacy assessments (including clinical tests, laboratory tests, and CT scans) will continue until PD is documented or subsequent anti-CLL therapy is initiated.
[0197] The end of the study will be defined as the later of the date of the last subject's last visit to complete post-treatment follow-up or the date of receipt of the last data point from the last subject required for the primary, secondary and / or exploratory analyses as pre-specified in the protocol.
[0198] Study Treatment: Subjects will begin treatment upon confirmation of eligibility.
[0199] Compound 1 will be supplied as a capsule for oral administration at the appropriate dosage. Compound 1 will be administered orally starting on day 15 of cycle 1 at 0.2 mg per day for 7 consecutive days, followed by 7 days off study drug every 14 days in each of the 28-day cycles (7 / 14 day design).
[0200] Obinutuzumab is administered by intravenous infusion. Obinutuzumab is administered on days 1, 2, 8, and 15 of cycle 1. Obinutuzumab is administered at a dose of 100 mg on day 1 of cycle 1, 900 mg on day 2 of cycle 1, and 1000 mg on each of day 8 of cycle 1 and day 15 of cycle 1. The dose of obinutuzumab on days 1 and 2 of cycle 1 may be adjusted according to institutional practice as long as the combined dose is 1000 mg. Subjects must receive a full starting dose of 1000 mg of obinutuzumab in cycle 1 at least 1 week prior to starting administration of compound 1. Obinutuzumab is administered at a dose of 1000 mg on days 1 of cycles 2-6.
[0201] All active and / or ongoing subjects with clinical benefit in the opinion of the investigator may continue to receive study treatment with compound 1 for up to 24 cycles, or 2 years of compound 1, or until discontinued for disease progression (PD), unacceptable toxicity, or other reasons, whichever occurs first. In the event that compound 1 is discontinued prior to obinutuzumab, obinutuzumab will also be discontinued. In the event that obinutuzumab is permanently discontinued, compound 1 may be continued. Subjects who achieve sustained minimal residual disease (MRD) negativity (in both peripheral blood and bone marrow) for a minimum period of 3 months have the option to discontinue study treatment; study treatment in these subjects may be resumed upon MRD positivity.
[0202] Summary of key efficacy evaluations: Efficacy evaluations included: 1) overall response rate (ORR) [complete response (CR), complete response with incomplete bone marrow recovery (CRi), nodal partial response (nPR), partial response (PR), partial response with lymphocytosis (PRL)] as assessed by the iwCLL 2018 guidelines (Tables 1 and 2); 2) clinical laboratory assessments; 3) tumor imaging assessments (CT scans); 4) bone marrow aspirate / biopsy at 1; 5) ECOG performance status; and 6) B symptom assessment.
[0203] Summary of Key Safety Assessments: Safety assessments included: 1) adverse events (AEs) using NCI CTCAE v5, unless otherwise specified, to select AEs; 2) vital signs; 3) physical examination; 4) concomitant medications and maneuvers; 5) electrocardiogram (ECG); 6) clinical laboratory assessments (including hematology and clinical chemistry assessments with renal and hepatic function assessments); 7) pregnancy test; and 8) left ventricular ejection fraction (LVEF).
[0204] Pharmacokinetic evaluation overview: Blood samples will be collected following intensive and sparse sampling methods to characterize the PK of compound 1 when administered in combination with obinutuzumab. Obinutuzumab serum concentrations will be measured at specific time points. Trends in the exposure-response relationships of compound 1 and markers of efficacy, safety and biological response will also be evaluated. Clinical response measures (efficacy and toxicity) and exposure-response relationships with biomarkers may be examined.
[0205] A number of references have been cited, the disclosures of which are incorporated herein by reference in their entirety.
[0206] The embodiments described above are merely illustrative, and those skilled in the art will recognize, or be able to ascertain using no more than routine experimentation, many equivalents to the specific compounds, materials, and procedures. All such equivalents are considered to be within the scope of the invention and encompassed by the appended claims.
Claims
1. formula: 【Chemistry 1】 2. A pharmaceutical composition for treating chronic lymphocytic leukemia / small lymphocytic lymphoma (CLL / SLL), comprising compound 3, represented by the formula:
2. formula: 【Chemistry 2】 2. A pharmaceutical composition for treating chronic lymphocytic leukemia / small lymphocytic lymphoma (CLL / SLL), comprising compound 1, represented by the formula:
3. formula: 【Chemistry 3】 2. A pharmaceutical composition for treating chronic lymphocytic leukemia / small lymphocytic lymphoma (CLL / SLL), comprising compound 2, represented by the formula:
4. formula 【Chemistry 4】 The pharmaceutical composition of claim 2, comprising compound 1 represented by the formula:
5. formula 【Chemistry 5】 3. The pharmaceutical composition of claim 2, comprising a pharma- ceutically acceptable salt of compound 1,
6. The pharmaceutical composition according to any one of claims 1 to 5, wherein the CLL / SLL is relapsed or refractory CLL / SLL.
7. 7. The pharmaceutical composition of claim 6, wherein the CLL / SLL is relapsed or refractory to at least two prior therapies.
8. 8. The pharmaceutical composition of claim 7, wherein the at least one prior therapeutic agent is a Bruton's tyrosine kinase (BTK) inhibitor, a phosphoinositide 3-kinase inhibitor, or venetoclax.
9. 9. The pharmaceutical composition of claim 8, wherein the BTK inhibitor is ibrutinib, acalabrutinib, zanubrutinib, or tirabrutinib.
10. The pharmaceutical composition according to any one of claims 1 to 5, wherein the CLL is newly diagnosed.
11. The pharmaceutical composition according to any one of claims 1 to 10, wherein the pharmaceutical composition is administered orally.
12. The pharmaceutical composition according to any one of claims 1 to 11, wherein the pharmaceutical composition is administered once a day for 5 days, followed by 2 days of rest.
13. The pharmaceutical composition according to any one of claims 1 to 11, wherein the pharmaceutical composition is administered once daily for 7 days, followed by 7 days of rest.
14. The pharmaceutical composition according to any one of claims 1 to 11, wherein the pharmaceutical composition is administered once daily for 5 days, followed by 9 days of rest.
15. The pharmaceutical composition according to any one of claims 1 to 11, wherein the pharmaceutical composition is administered once daily for 14 days, followed by 14 days of rest.
16. The pharmaceutical composition according to any one of claims 1 to 11, wherein the pharmaceutical composition is administered once daily for 21 days, followed by 7 days of rest.
17. 12. The pharmaceutical composition of any one of claims 1 to 11, wherein the pharmaceutical composition is administered on days 1 to 5 of a 7-day cycle, on days 1 to 3 of a 7-day cycle, on days 1 to 5 of a 14-day cycle, on days 1 to 7 of a 14-day cycle, on days 1 to 10 of a 14-day cycle, on days 1 to 7 and on days 15 to 21 of a 28-day cycle, on days 1 to 21 of a 28-day cycle, or on days 1 to 14 of a 28-day cycle.
18. 18. The pharmaceutical composition of any one of claims 1 to 17, wherein the pharmaceutical composition is used such that the compound is administered in an amount of about 0.1 mg, about 0.2 mg, about 0.4 mg, about 0.6 mg, about 0.8 mg, about 1.2 mg or about 1.6 mg per day.
19. The pharmaceutical composition of any one of claims 1 to 18, wherein the pharmaceutical composition is administered in combination with obinutuzumab.
20. 20. The pharmaceutical composition of claim 19, wherein obinutuzumab is administered intravenously.
21. 20. The pharmaceutical composition of claim 19, wherein obinutuzumab is administered at a dose of about 100 mg on day 1 of a first 28 day cycle, at a dose of about 900 mg on day 2 of the first 28 day cycle, and at a dose of about 1000 mg on each of days 8 and 15 of the first 28 day cycle and on the first day of the second through sixth 28 day cycles.
22. 20. The pharmaceutical composition of claim 19, wherein: (i) obinutuzumab is administered at a dose of about 100 mg on day 1, about 900 mg on day 2, and about 1000 mg on each of days 8 and 15 of an initial 28 day cycle ("cycle 1"), followed by a dose of about 1000 mg on day 1 of each subsequent 28 day cycle; and (ii) the pharmaceutical composition is administered once daily for 7 days, followed by 7 days of rest, starting on day 15 of cycle 1.
23. 20. The pharmaceutical composition of claim 19, wherein: (i) obinutuzumab is administered at a dose of about 100 mg on day 1, about 900 mg on day 2, and about 1000 mg on each of days 8 and 15 of an initial 28 day cycle ("cycle 1"), followed by a dose of about 1000 mg on day 1 of each subsequent 28 day cycle; and (ii) the pharmaceutical composition is administered once daily for 5 days, followed by 9 days of rest, starting on day 15 of cycle 1.
24. 20. The pharmaceutical composition of claim 19, wherein: (i) obinutuzumab is administered at a dose of about 100 mg on day 1, about 900 mg on day 2, and about 1000 mg on each of days 8 and 15 of an initial 28 day cycle ("cycle 1"), followed by a dose of about 1000 mg on day 1 of each subsequent 28 day cycle; and (ii) the pharmaceutical composition is administered once daily for 14 days, followed by 14 days of rest, starting on day 15 of cycle 1.
25. 20. The pharmaceutical composition of claim 19, wherein: (i) obinutuzumab is administered at a dose of about 100 mg on day 1, about 900 mg on day 2, and about 1000 mg on each of days 8 and 15 of an initial 28 day cycle ("cycle 1"), followed by a dose of about 1000 mg on day 1 of each subsequent 28 day cycle; and (ii) the pharmaceutical composition is administered once daily for 21 days, followed by 7 days of rest, starting on day 15 of cycle 1.
Citation Information
Patent Citations
Use of Bruton's tyrosine kinase (Btk) inhibitors
JP2013527249A
Methods for treating non-hodgkin's lymphoma using 2-(2,6-dioxopiperidin-3-yl)-4-((2-fluoro-4-((3-morpholinoazetidin-1-yl)methyl)benzyl)amino)isoindoline-1,3-dione
JP2022527398A
Methods of treating hematologic malignancies with 2-(2,6-dioxopiperidin-3-yl)-4-((2-fluoro-4-((3-morpholinoazetidin-1-yl)methyl)benzyl)amino)isoindoline-1,3-dione
JP2022552882A
Pharmaceutical Compositions Comprising (S)-2-(2,6-Dioxopiperidin-3-yl)-4-((2-fluoro-4-((3-morpholinoazetidin-1-yl)methyl)benzyl)amino)isoindoline-1,3-dione and Methods of Use Thereof
JP2022552884A
JPP7458324B
Cited By
Pharmaceutical Compositions Comprising (S)-2-(2,6-Dioxopiperidin-3-yl)-4-((2-fluoro-4-((3-morpholinoazetidin-1-yl)methyl)benzyl)amino)isoindoline-1,3-dione and Methods of Use Thereof
JP2022552884A
